WO2012056229A1 - Inflammatory disease - Google Patents
Inflammatory disease Download PDFInfo
- Publication number
- WO2012056229A1 WO2012056229A1 PCT/GB2011/052073 GB2011052073W WO2012056229A1 WO 2012056229 A1 WO2012056229 A1 WO 2012056229A1 GB 2011052073 W GB2011052073 W GB 2011052073W WO 2012056229 A1 WO2012056229 A1 WO 2012056229A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- compound according
- thl
- group
- combined
- Prior art date
Links
- 208000027866 inflammatory disease Diseases 0.000 title claims abstract description 18
- 150000001875 compounds Chemical class 0.000 claims abstract description 116
- 230000001404 mediated effect Effects 0.000 claims abstract description 48
- 238000000034 method Methods 0.000 claims abstract description 12
- 102000003814 Interleukin-10 Human genes 0.000 claims description 79
- 108090000174 Interleukin-10 Proteins 0.000 claims description 79
- 229940076144 interleukin-10 Drugs 0.000 claims description 76
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 45
- 201000010099 disease Diseases 0.000 claims description 42
- 239000000203 mixture Substances 0.000 claims description 28
- 102000004127 Cytokines Human genes 0.000 claims description 25
- 108090000695 Cytokines Proteins 0.000 claims description 25
- 239000003981 vehicle Substances 0.000 claims description 24
- 238000004519 manufacturing process Methods 0.000 claims description 23
- 210000002540 macrophage Anatomy 0.000 claims description 21
- 210000004241 Th2 cell Anatomy 0.000 claims description 19
- 210000004443 dendritic cell Anatomy 0.000 claims description 19
- 108010065805 Interleukin-12 Proteins 0.000 claims description 16
- 201000006417 multiple sclerosis Diseases 0.000 claims description 16
- 230000004044 response Effects 0.000 claims description 15
- 125000000217 alkyl group Chemical group 0.000 claims description 14
- 230000001965 increasing effect Effects 0.000 claims description 14
- 239000011159 matrix material Substances 0.000 claims description 14
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 12
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 11
- 229910052757 nitrogen Inorganic materials 0.000 claims description 11
- 229910052736 halogen Inorganic materials 0.000 claims description 10
- 150000002367 halogens Chemical class 0.000 claims description 10
- 230000031261 interleukin-10 production Effects 0.000 claims description 10
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- SNPPWIUOZRMYNY-UHFFFAOYSA-N bupropion Chemical compound CC(C)(C)NC(C)C(=O)C1=CC=CC(Cl)=C1 SNPPWIUOZRMYNY-UHFFFAOYSA-N 0.000 claims description 9
- 125000004432 carbon atom Chemical group C* 0.000 claims description 9
- 241000700605 Viruses Species 0.000 claims description 8
- 238000012377 drug delivery Methods 0.000 claims description 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 8
- 206010040070 Septic Shock Diseases 0.000 claims description 7
- 239000000463 material Substances 0.000 claims description 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 7
- 230000036303 septic shock Effects 0.000 claims description 7
- 208000011231 Crohn disease Diseases 0.000 claims description 6
- 125000003545 alkoxy group Chemical group 0.000 claims description 6
- 239000008273 gelatin Substances 0.000 claims description 6
- 229920000159 gelatin Polymers 0.000 claims description 6
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 5
- 108010010803 Gelatin Proteins 0.000 claims description 5
- 150000001721 carbon Chemical group 0.000 claims description 5
- 229910052799 carbon Inorganic materials 0.000 claims description 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 5
- 235000019322 gelatine Nutrition 0.000 claims description 5
- 235000011852 gelatine desserts Nutrition 0.000 claims description 5
- 230000001939 inductive effect Effects 0.000 claims description 5
- 239000002207 metabolite Substances 0.000 claims description 5
- -1 polyethylene glycol) Chemical compound 0.000 claims description 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 5
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 4
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical class O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 claims description 4
- 206010036600 Premature labour Diseases 0.000 claims description 4
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 4
- 125000003277 amino group Chemical group 0.000 claims description 4
- 229960001058 bupropion Drugs 0.000 claims description 4
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 4
- 239000000499 gel Substances 0.000 claims description 4
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims description 4
- 208000023504 respiratory system disease Diseases 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 208000011580 syndromic disease Diseases 0.000 claims description 4
- 230000009885 systemic effect Effects 0.000 claims description 4
- 201000003883 Cystic fibrosis Diseases 0.000 claims description 3
- 201000004681 Psoriasis Diseases 0.000 claims description 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 3
- 230000036760 body temperature Effects 0.000 claims description 3
- 125000005842 heteroatom Chemical group 0.000 claims description 3
- 230000002757 inflammatory effect Effects 0.000 claims description 3
- 238000002844 melting Methods 0.000 claims description 3
- 230000008018 melting Effects 0.000 claims description 3
- 239000003346 palm kernel oil Substances 0.000 claims description 3
- 235000019865 palm kernel oil Nutrition 0.000 claims description 3
- 230000003076 paracrine Effects 0.000 claims description 3
- 229920001223 polyethylene glycol Polymers 0.000 claims description 3
- 239000012453 solvate Substances 0.000 claims description 3
- 201000001178 Bacterial Pneumonia Diseases 0.000 claims description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 2
- 206010012310 Dengue fever Diseases 0.000 claims description 2
- 201000009273 Endometriosis Diseases 0.000 claims description 2
- 208000001688 Herpes Genitalis Diseases 0.000 claims description 2
- 206010020751 Hypersensitivity Diseases 0.000 claims description 2
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 claims description 2
- 206010027202 Meningitis bacterial Diseases 0.000 claims description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims description 2
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims description 2
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims description 2
- 206010040047 Sepsis Diseases 0.000 claims description 2
- 208000009714 Severe Dengue Diseases 0.000 claims description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 2
- 102100040247 Tumor necrosis factor Human genes 0.000 claims description 2
- 206010046851 Uveitis Diseases 0.000 claims description 2
- 206010064930 age-related macular degeneration Diseases 0.000 claims description 2
- 230000007815 allergy Effects 0.000 claims description 2
- 125000003118 aryl group Chemical group 0.000 claims description 2
- 208000006673 asthma Diseases 0.000 claims description 2
- 201000009904 bacterial meningitis Diseases 0.000 claims description 2
- 125000005708 carbonyloxy group Chemical group [*:2]OC([*:1])=O 0.000 claims description 2
- 125000000392 cycloalkenyl group Chemical group 0.000 claims description 2
- 230000016396 cytokine production Effects 0.000 claims description 2
- 201000002950 dengue hemorrhagic fever Diseases 0.000 claims description 2
- 206010012601 diabetes mellitus Diseases 0.000 claims description 2
- 201000004946 genital herpes Diseases 0.000 claims description 2
- 239000008359 glycogelatin Substances 0.000 claims description 2
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 2
- 208000002780 macular degeneration Diseases 0.000 claims description 2
- 201000007094 prostatitis Diseases 0.000 claims description 2
- 230000005070 ripening Effects 0.000 claims description 2
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims description 2
- 239000006213 vaginal ring Substances 0.000 claims description 2
- 229940044953 vaginal ring Drugs 0.000 claims description 2
- 241000725643 Respiratory syncytial virus Species 0.000 claims 2
- WQNLQPZOYRYJJB-UHFFFAOYSA-N 1-amino-1-(3-chlorophenyl)propan-1-ol Chemical compound CCC(N)(O)C1=CC=CC(Cl)=C1 WQNLQPZOYRYJJB-UHFFFAOYSA-N 0.000 claims 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims 1
- 239000002202 Polyethylene glycol Substances 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 229940116364 hard fat Drugs 0.000 claims 1
- 229960003511 macrogol Drugs 0.000 claims 1
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 abstract description 4
- OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical class CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 abstract description 3
- ULSIYEODSMZIPX-UHFFFAOYSA-N phenylethanolamine Chemical compound NCC(O)C1=CC=CC=C1 ULSIYEODSMZIPX-UHFFFAOYSA-N 0.000 abstract description 3
- 230000000694 effects Effects 0.000 description 35
- 241000699670 Mus sp. Species 0.000 description 30
- 239000002158 endotoxin Substances 0.000 description 22
- 229920006008 lipopolysaccharide Polymers 0.000 description 22
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 18
- 206010009887 colitis Diseases 0.000 description 14
- 239000007788 liquid Substances 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 13
- NHJVRSWLHSJWIN-UHFFFAOYSA-N 2,4,6-trinitrobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O NHJVRSWLHSJWIN-UHFFFAOYSA-N 0.000 description 12
- 230000037396 body weight Effects 0.000 description 12
- 241001465754 Metazoa Species 0.000 description 11
- 210000004369 blood Anatomy 0.000 description 10
- 239000008280 blood Substances 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 9
- 238000001727 in vivo Methods 0.000 description 9
- 230000002354 daily effect Effects 0.000 description 8
- NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 description 8
- 229960001940 sulfasalazine Drugs 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 108700012920 TNF Proteins 0.000 description 7
- 210000003719 b-lymphocyte Anatomy 0.000 description 7
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 7
- 229960003957 dexamethasone Drugs 0.000 description 7
- 208000015181 infectious disease Diseases 0.000 description 7
- 244000052769 pathogen Species 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 206010061218 Inflammation Diseases 0.000 description 6
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 6
- 208000036142 Viral infection Diseases 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 210000000987 immune system Anatomy 0.000 description 6
- 230000006698 induction Effects 0.000 description 6
- 230000004936 stimulating effect Effects 0.000 description 6
- 229910021653 sulphate ion Inorganic materials 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- 230000009385 viral infection Effects 0.000 description 6
- 229920002307 Dextran Polymers 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 108010010974 Proteolipids Proteins 0.000 description 5
- 102000016202 Proteolipids Human genes 0.000 description 5
- 210000001744 T-lymphocyte Anatomy 0.000 description 5
- 201000002491 encephalomyelitis Diseases 0.000 description 5
- 210000004698 lymphocyte Anatomy 0.000 description 5
- 239000003226 mitogen Substances 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 239000000427 antigen Substances 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 230000036039 immunity Effects 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 206010022000 influenza Diseases 0.000 description 4
- 238000007911 parenteral administration Methods 0.000 description 4
- 230000001717 pathogenic effect Effects 0.000 description 4
- 210000002381 plasma Anatomy 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 206010012735 Diarrhoea Diseases 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 206010042674 Swelling Diseases 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 230000002917 arthritic effect Effects 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 description 3
- 239000002131 composite material Substances 0.000 description 3
- 239000003246 corticosteroid Substances 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 239000003925 fat Substances 0.000 description 3
- 235000019197 fats Nutrition 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 238000010172 mouse model Methods 0.000 description 3
- 230000003472 neutralizing effect Effects 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 125000000286 phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 239000008174 sterile solution Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000000375 suspending agent Substances 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 208000016261 weight loss Diseases 0.000 description 3
- 230000004580 weight loss Effects 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 2
- 208000030767 Autoimmune encephalitis Diseases 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 108010081690 Pertussis Toxin Proteins 0.000 description 2
- BHHGXPLMPWCGHP-UHFFFAOYSA-N Phenethylamine Chemical class NCCC1=CC=CC=C1 BHHGXPLMPWCGHP-UHFFFAOYSA-N 0.000 description 2
- 206010038063 Rectal haemorrhage Diseases 0.000 description 2
- 241000700584 Simplexvirus Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000033289 adaptive immune response Effects 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 230000008499 blood brain barrier function Effects 0.000 description 2
- 210000001218 blood-brain barrier Anatomy 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 230000008951 colonic inflammation Effects 0.000 description 2
- 230000008984 colonic lesion Effects 0.000 description 2
- 238000007906 compression Methods 0.000 description 2
- 230000006835 compression Effects 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 208000012997 experimental autoimmune encephalomyelitis Diseases 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 210000002443 helper t lymphocyte Anatomy 0.000 description 2
- 230000028996 humoral immune response Effects 0.000 description 2
- 230000004727 humoral immunity Effects 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 230000006058 immune tolerance Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000015788 innate immune response Effects 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 210000003141 lower extremity Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 230000011278 mitosis Effects 0.000 description 2
- 230000004682 mucosal barrier function Effects 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 244000045947 parasite Species 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000009097 single-agent therapy Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000008247 solid mixture Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 108700012359 toxins Proteins 0.000 description 2
- 230000029069 type 2 immune response Effects 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- 125000006528 (C2-C6) alkyl group Chemical group 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 235000003911 Arachis Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 description 1
- FYTJIWJLGWYTCT-UHFFFAOYSA-N CCc1c(CC)cc(CC(C)C2)c2c1 Chemical compound CCc1c(CC)cc(CC(C)C2)c2c1 FYTJIWJLGWYTCT-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010019973 Herpes virus infection Diseases 0.000 description 1
- 101001033233 Homo sapiens Interleukin-10 Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 230000004163 JAK-STAT signaling pathway Effects 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 102000043136 MAP kinase family Human genes 0.000 description 1
- 108091054455 MAP kinase family Proteins 0.000 description 1
- 102000043131 MHC class II family Human genes 0.000 description 1
- 108091054438 MHC class II family Proteins 0.000 description 1
- 206010027926 Monoplegia Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 208000007542 Paresis Diseases 0.000 description 1
- 206010037714 Quadriplegia Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 210000005006 adaptive immune system Anatomy 0.000 description 1
- 230000004721 adaptive immunity Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- YVPYQUNUQOZFHG-UHFFFAOYSA-N amidotrizoic acid Chemical compound CC(=O)NC1=C(I)C(NC(C)=O)=C(I)C(C(O)=O)=C1I YVPYQUNUQOZFHG-UHFFFAOYSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000767 anti-ulcer Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000003833 bile salt Substances 0.000 description 1
- 229940093761 bile salts Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 229960004436 budesonide Drugs 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 238000012754 cardiac puncture Methods 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 230000035606 childbirth Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 210000004921 distal colon Anatomy 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 210000003162 effector t lymphocyte Anatomy 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 150000008282 halocarbons Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000005462 in vivo assay Methods 0.000 description 1
- 210000005007 innate immune system Anatomy 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000008611 intercellular interaction Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 208000027906 leg weakness Diseases 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical class CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 238000012261 overproduction Methods 0.000 description 1
- 230000014306 paracrine signaling Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000004983 pleiotropic effect Effects 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920006316 polyvinylpyrrolidine Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- FDDDEECHVMSUSB-UHFFFAOYSA-N sulfanilamide Chemical compound NC1=CC=C(S(N)(=O)=O)C=C1 FDDDEECHVMSUSB-UHFFFAOYSA-N 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 230000002618 waking effect Effects 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
- A61K9/0036—Devices retained in the vagina or cervix for a prolonged period, e.g. intravaginal rings, medicated tampons, medicated diaphragms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- the present invention relates to the treatment of inflammatory diseases, and especially Th- 1 mediated inflammatory diseases.
- the invention relates to the treatment of Th-1 mediated inflammatory diseases using a range of related 1 -phenyl-2-amino ethanol, e hanal and ethane derivatives, and to the use of these compounds in methods of treatment.
- the defence against disease is critical for the survival of all animals, and the mechanism employed for this purpose is the animal immune system.
- the immune system is complex, and involves two main divisions, (i) innate immunity, and (h) adaptive immunity.
- the innate immune system includes the cells and mechanisms that defend the host from infection by invading organisms, in a non-specific manner.
- Leukocytes which are involved with the innate system, include inter alia phagocytic cells, such as macrophages, neutrophils and dendritic cells.
- the innate system is fully functional before a pathogen enters the host.
- lymphocytes the two main categories of which are B cells and T Cells.
- B cells are involved in the creation of neutralising antibodies that circulate in blood plasma and lymph and form part of the humoral immune response.
- T cells play a role in both the humoral immune response and in cell-mediated immunity.
- activator or effector T cells including cytotoxic T cells (CD8+) and "helper" T cells (CD4+), of which there are two main types known as Type 1 helper T cells (Thl) and Type 2 helper T cell (Th2).
- Thl cells promote a cell-mediated adaptive immune response, which involves the activation of macrophages and stimulates the release of various cytokines, such as IFNy, TNF- and IL- 2, in response to an antigen. These cytokines influence the function of other cells in the adaptive and innate immune responses, and result in the destruction of micro- organisms.
- Thl responses are more effective against intracellular pathogens, such as viruses and bacteria present inside host cells.
- a Th2 response is characterised by the release of IL-4, which results in the activation of B cells to make neutralising antibodies, which lead the humoral immunity.
- Th2 responses are more effective against extracellular pathogens, such as parasites and toxins located outside host cells. Accordingly, the humoral and cell-mediated responses provide quite different mechanisms against an invading pathogen.
- Interleukin-10 also known as human cytokine synthesis inhibitory factor (CSIF)
- CCF human cytokine synthesis inhibitory factor
- IL-10 down-regulates the expression of Thl cytokines (such as IFNy, TNF-oc and IL-12), MHC class II antigens, and co-stimulatory molecules on macrophages. It also enhances B cell survival, proliferation, and antibody production.
- Thl cytokines such as IFNy, TNF-oc and IL-12
- MHC class II antigens MHC class II antigens
- co-stimulatory molecules on macrophages. It also enhances B cell survival, proliferation, and antibody production.
- IL-10 can block NF- ⁇ activity, and is involved in the regulation of the JAK-STAT signaling pathway.
- IL-10 is a validated target in inflammatory disease, and has been shown to be essential for immunotolerance and the control of Thl immunity (O'Garra et al., 2008, Immunol. Rev., 223:114-31).
- Systemic adnoinistration of exogenous IL-10 in early clinical trials showed some initial promise in the treatment of various diseases, including rheumatoid arthritis, Crohn's disease, psoriasis and cystic fibrosis.
- problems associated with these early trials were that systemically administered exogenous IL-10 did not dampen exaggerated Thl responses as predicted, possibly because tissue levels of IL-10 were too low (the half-life of IL-10 is short), or because IL-10 was not presented in the correct manner.
- concentrations of IFNy, TNF-ot and IL-12 actually increased to deleterious levels. Furthermore, a significant side effect of administering too much exogenous IL-10 is that it actually suppresses the immune system, rather than positively modulating it, and so results in serious immune-related problems.
- a compound which is capable of increasing interleukin-10 (IL-10) production for use in treating a Thl-mediated disease, wherein the IL-10 is endogenously produced by Th2 cells, dendritic cells and/or macrophages.
- IL-10 interleukin-10
- a method of preventing, treating and/or ameliorating a Thl-mediated disease comprising administering, to a subject in need of such treatment, a therapeutically effective amount of a compound which is capable of increasing interleukin-10 (IL-10) production, wherein the IL-10 is
- Th2 cells endogenously produced by Th2 cells, dendritic cells and/ or macrophages.
- a compound which is capable of inducing endogenous production of interleukin-10 (IL-10) by Th2 cells, dendritic cells and/or macrophages, for treating a Th-1 mediated disease.
- IL-10 interleukin-10
- IL-10 production is a characteristic that indicates a switch from a Thl to a Th2 response. They have demonstrated that inducing the switch from a Thl to a Th2 response by up-regulating IL-10 production can be used to help treat Thl-mediated hyper-inflammation.
- B cells are activated, which produce neutralising antibodies, which lead the humoral immunity.
- Th2 responses are much more effective against extracellular pathogens, such as parasites and toxins located outside host cells, than Thl responses.
- Thl-mediated hyper-inflammation occurs during viral infections, and so the inventors believe that endogenously producing IL-10 by the Th2 cells upon adrninistration of the compound to the subject could be used to treat a respiratory collapse caused by a viral infection.
- some viruses such as Herpes Simplex Virus (HSV)
- HSV Herpes Simplex Virus
- IL-10 is a paracrine cytokine, and that, therefore, the compound used in the first, second and third aspects of the invention can be effectively used to increase endogenous IL-10 production in a paracrine manner.
- paracrine signalling can be a form of cell signalling in which the target cell is near or local to the signal-releasing cell.
- IL-10 can control the immune response at sites of inflammation in tandem with cell-cell interactions.
- the compound which is capable of increasing endogenous IL-10 production is recognised by Th2 cells, dendritic cells and/ or macrophages.
- Th2 cells, dendritic cells and/or macrophages may phagocytise the compound, react with pathways in each of these cell types, and thereby endogenously produce IL-10.
- the IL-10 is produced by Th2 cells, dendritic cells and/or macrophages, which are immunocompetent.
- IL-10 in contrast to producing IL-10 by non-immune cells, which causes an imbalance in the immune system leading to infections and, in some cases cancer, endogenous production of IL-10 by immuno-competent Th2 cells, dendritic cells and/or macrophages, ensures that the immune system remains balanced, thereby avoiding infection.
- the immune system is capable of regulating itself naturally, thereby reducing the risk of infections and cancer.
- the levels of IL-10 generated due to the regulator ) ' process and feedback loops may modulate (e.g. decrease) Thl cytokine concentration, such as IFNy, T F-a and IL-12, but not suppress their production completely. This may be important because these Thl cytokines are needed to protect the body from infection.
- Thl cytokine concentration such as IFNy, T F-a and IL-12
- the compound which is capable of increasing endogenous IL-10 production, may comprise a compound of formula I:-
- R 1 is H, or combined with R 2 ;
- R 2 is H, OH, a halogen, a substituted or unsubstituted amino group, a C j.5 alkyl or alkoxyl group, optionally substituted with one or more O, OH, amino and/ or optionally C,_ 3 alkyl substituted phenyl group, or combined with R 1 ;
- R 3 and R 4 are each independendy H, OH, a halogen, a substituted or unsubstituted amino group, or a C, ⁇ alkyl or alkoxyl group, optionally substituted with one or more O, OH, amino and/ or optionally C, .3 alkyl substituted phenyl group;
- R 5 is H
- R 6 is H, a C,_s alkyl group, or combined with R 8 ;
- R 7 is H, or combined with R 8 ;
- R 8 is combined with R 6 or R 7 , or is a straight chain, branched or cyclo- C,-C 9 alkyl group, optionally including one or more hetero atom in its carbon skeleton and optionally substituted with one or more OH, and/or C 5 _ 6 aryl group, optionally substituted with one or more OH or C, 5 alkoxyl or alkyl group;
- R' and R 2 together with the associated ring carbon atoms, form an optionally O substituted cycloalkyl, cycloalkenyl, cycloheteroalkyl or cycloheteroalkenyl group of 5 or 6 carbon atoms, or 4 or 5 carbon atoms and a hetero atom;
- R 6 and R 8 when combined, R 6 and R 8 , together with the nitrogen atom carrying R 8 and the carbon atom carrying R 6 , form a 5 or 6 membered cycloheteroalkyl group;
- R 7 and R 8 when combined, R 7 and R 8 , together with the nitrogen atom carrying them, form an optionally benzyl substituted 5 or 6 membered cycloheteroalkyl group;
- R 2 is more preferably H, OH or CI.
- R 3 is preferably H, NH 2 , OH or CH 3 PhCOO-.
- R 3 is more preferably H, NH, or OH.
- R 4 is preferably H, OH, NH 2 COO-, or a halogen, preferably, chlorine.
- R 4 is more preferably H or CI.
- R 6 is preferably methyl, ethyl, or H, more preferably, methyl or ethyl and most preferably methyl.
- R 7 is preferably H.
- R 8 is preferably straight chain or branched C 2 -C 6 alkyl group, optionally substituted with OH, phenyl, PhOH or PhOCH 3 .
- R 8 is more preferably tert. butyl, isopropyl, -C(CH 3 ) 2 OH, - CH 2 PhOCH 3 ,-(CH 2 ) 2 PhOH, -CH(CH 3 )CH 2 CH 2 Ph, or -CH(CH 3 )CH 2 CH 2 PhOH and, most preferably, tert. butyl, -C(CH 3 ) 2 OH, -(CH,) 2 PhOH, -CH(CH 3 )CH 2 CH 2 Ph, or - CH(CH 3 )CH 2 CH 2 PhOH.
- R 8 can also be:-
- R 1 and R 2 preferably form the group:-
- R 6 and R 8 When R 6 and R 8 are combined it is preferred that, together with the nitrogen atom carrying R 8 and the carbon atom carrying R 6 , they form a cycloheteroalkyl group of 5 carbon atoms and 1 nitrogen atom. When R' and R 8 are combined it is preferred that they form the group:-
- Ph means phenyl and it is preferred that, when bi-substituted, any such phenyl group is 1, 4-substituted.
- the present invention involves a compound of formula I wherein:- X is CO, CHOH or CH 2 ; R' is H;
- R 2 is H, OH, or a halogen
- R 3 is H, OH or NH 2 ;
- R 4 is H, or a halogen
- R 5 is H
- R > is H, methyl or ethyl, or combined with R 8 ;
- R 7 is H, or combined with R 8 ;
- R 8 is combined with R 6 or R 7 , or is tert. butyl, -C(CH 3 ) 2 OH, -(CH ⁇ PhOH, - CH(CH 3 )CH 2 CH 2 Ph, or -CH(CH 3 )CH 2 CH 2 PhOH;
- R 6 and R 8 when combined, R 6 and R 8 , together with the nitrogen atom carrying R 8 and the carbon atom carrying R 6 , form a cycloheteroalkyl group of 5 carbon atoms and 1 nitrogen atom;
- R s In all embodiments of the invention where R s is not combined with R 8 , it is preferred for R s to be a methyl or an ethyl gtoup, preferably a methyl group. In such preferred embodiments, it is also preferred that R 1 , R 4 , R 5 and R 7 are H, R 2 is H or OH, and R 3 is OH. In such preferred embodiments R 8 can be -(CH ⁇ PhOH or - CH(CH 3 )CH 2 CH 2 PhOH.
- the inventors studied the effects of erytbro 2-(l,l- dimethylemyl)aniino-l-(3-chlorophenyr)propan-l-ol (denoted herein as BC1053, shown in Figure 1) and demonstrated in in vim and ex vivo models that (i) this compound surprisingly induces endogenous production of IL-10 by Th2 cells, dendritic cells and/or macrophages and (ii) the concentrations of the Thl cytokines, TNF-CC and IL- 2, were potently inhibited.
- the invention is based on the induction of Th2 immune cells to trigger the switch from a Thl to a Th2 immune response, and to thereby treat Thl -mediated hyper- inflammation, which is driven by these Thl cytokines.
- the inventors therefore believe that they are the first to demonstrate that, in addition to sharing other properties, the defined 1 -phenyl-2-amino ethanol, ethanal and ethane derivatives represented by Formula I can be used to stimulate endogenous production of IL-10, and reduce Thl cytokine production, and to thereby induce the switch from a Thl to a Th2 response, in such a way so as to be useful in the treatment of Thl -mediated inflammatory disease.
- these compounds may be used to combat respiratory disorders that are caused by acute viral infections, and which, in some cases (e.g. influenza infections), can cause death.
- Various metabolites of compound (I) i.e. any compound of formula (I)
- Compound (I), for use, in the invention may be chiral.
- the compound (I) may include any diastereomer and enantiomer of the formula represented by (I).
- Diastereomers or enantiomers of (I) are believed to display potent cytokine modulatory activity, and such activities may be determined by use of appropriate in vitro and in vivo assays, which will be known to the skilled technician. It will also be appreciated that compounds for use in the invention may also include pharmaceutically active salts, e.g. the hydrochloride.
- the compound represented by formula (I) may be the drug that is known and available under the trade name, bupropion. Bupropion is known to be metabolised in vivo into a number of different metabolites also of formula (I), an embodiment of which is shown in Figure 1. Therefore, buproprion or any of these metabolites may also be used for treating acute viral infections in accordance with the invention.
- Bupropion is metabolised non-stereoselectively to a number of enantiomers, but these compounds represent a relatively small proportion of the total metabolism of the parent drug.
- Compounds defined by formula (I) can therefore include these metabolites as racemates or as pairs of diastereoisomers or individual enantiomers, including the tbreo- and erytbrv-pah of diastereoisomers and the individual tbreo and erythro enantiomers. It is preferred that the compound defined by formula (I) includes the erythro enantiomer or enantiomers. - Si -
- Exemplary bupropion metabolites include 2-(l,l-dime ylemyl)amino-l-(3- chlorophenyl)propan-l -ol, 2-(l ,1 -dimemyl-2-hydroxyethyl)amino-l -(3- chlorophenyl)propan-l -one, (1 S,2R)-erythto-2-(l ,1 -dimemylemyl)amino ⁇ l-(3- chlorophenyl)propan-l -ol, (1 R,2S)-erythro-2-(l ,1 -d1 ⁇ 2iethylemyl)arnino-l -(3- chlorophenyl)propan-l-ol, (lS,2S)-tJiieo-2-(l,l-dimemylemyl)arnino-l-(3- chlorophenyl)propan-l -ol and (1 R,2R)-
- compound (I) may be hydrobupropion (i.e. 2-(l,l- dimemylemyl)amino-l-(3-chlorophenyl)propan-l-ol).
- hydrobupropion i.e. 2-(l,l- dimemylemyl)amino-l-(3-chlorophenyl)propan-l-ol.
- One isomer of hydrobupropion may be (+)- ⁇ reo-hydrobupropion, i.e. (R, R-hydrobupropion), and another isomer may be
- the bupropion metabolite employed in any aspect of the invention is an R enantiomer, either at the first and/or second position.
- the Thl -mediated disease which may be treated, may be a Thl- mediated inflammatory disease, preferably systemic inflammatory disease.
- the inventors have conducted several experiments in mice models which are known to be representative of human disease, for example septic shock, rheumatoid arthritis (RA), arthritic swelling, inflammatory bowel disease (IBD) and multiple sclerosis (MS).
- the disease to be treated may be selected from a group of Thl -mediated diseases consisting of rheumatoid arthritis (RA); psoriatic arthritis; psoriasis; inflammatory bowel syndrome (IBD); Crohn's disease; ulcerative colitis; multiple sclerosis (MS); flu, including pandemic flu; respiratory disorders, for example those caused by viruses, such as respirator ⁇ ' syncytial virus (RSV); cystic fibrosis; herpes, including genital herpes; asthma and allergies; sepsis and septic shock; bacterial pneumonia; bacterial meningitis; dengue hemorrhagic fever; diabetes Type I; endometriosis; prostatitis; uveitis; uterine ripening; and age-related macular degeneration.
- RA rheumatoid arthritis
- IBD inflammatory bowel syndrome
- MS ulcerative colitis
- flu including pandemic flu
- respiratory disorders for example those caused by viruses, such as respir
- the Thl -mediated disease may be virally, bacterially or chemically (e.g. environmentally) induced.
- a virus causing the Thl -mediated disease may cause a chronic or acute infection, which may cause a respiratory disorder.
- the virus causing the Thl- mediated disease may be Influenza.
- the Thl -mediated disease which may be treated, is systemic inflammatory disease, for example flarnmatory bowel syndrome (IBD) or rheumatoid arthritis ( A).
- IBD flarnmatory bowel syndrome
- A rheumatoid arthritis
- the active compound may be used to treat a Thl -mediated disease in a monotherapy (i.e. use of the compound capable of stimulating endogenous IL- 10 production alone).
- the compound may be used as an adjunct to, or in combination with, known therapies used in treating Thl-mediated diseases.
- the active compound may be combined in compositions having a number of different forms depending, in particular, on the manner in which the composition is to be used.
- the composition may be in the form of a powder, tablet, capsule, liquid, ointment, cream, gel, hydrogel, aerosol, spray, micellar solution, transdermal patch, liposome suspension or any other suitable form that may be administered to a person or animal in need of treatment.
- the vehicle for medicaments according to the invention should be one which is well-tolerated by the subject to whom it is given, and preferably enables delivery of the agents across the blood-brain barrier, or the lungs.
- compositions comprising the active compound may be used in a number of ways. For instance, oral adrninistration may be required in which case the compound may be contained within a composition that may, for example, be ingested orally in the form of a tablet, capsule or liquid. Alternatively, the composition may be administered by injection into the blood stream. Injections may be intravenous (bolus or infusion) or subcutaneous (bolus or infusion). Alternatively, the composition comprising the active compound may be administered by inhalation (e.g. intranasally, or by mouth). Compositions may also be formulated for topical use. For instance, ointments may be applied to the skin. Topical application to the skin is particularly useful for treating infections of the skin or as a means of transdermal delivery to other tissues.
- the amount of the active compound that is required is determined by its biological activity and bioavailability, which in turn depends on the mode of administration, the physicochemical properties of the compound and whether the compound is being used as a monotherapy, or in a combined therapy.
- the frequency of administration will also be influenced by the above-mentioned factors and particularly the half-life of the active compound within the subject being treated.
- Optimal dosages to be administered may be determined by those skilled in the art, and will vary with the particular active compound in use, the strength of the preparation, the mode of administration, and the advancement of the disease condition. Additional factors depending on the particular subject being treated will result in a need to adjust dosages, including subject age, weight, gender, diet, and time of adrninistration.
- a daily dose of between 0.00 ⁇ g/kg of body weight and 60mg/kg of body weight of the active compound may be used for the prevention and/or treatment of a Thl- mediated disease depending upon which compound is used.
- the daily dose is between 0.01
- Daily doses of the active compound may be given as a single administration (e.g. a single daily injection or a single inhalation).
- a suitable daily dose may be between 0.07 ⁇ g and 700mg (i.e. assuming a body weight of 70kg), or between 0.7C ⁇ g and 500mg, or between lOmg nd 450mg.
- medicaments comprising the active compound may be administered more than once to the subject in need of treatment.
- the compound may require administration twice or more times during a day.
- the active compound may be administered as two (or more depending upon the severity of the viral infection being treated) daily doses of between 0.( ⁇ g and 700mg (i.e. assuming a body weight of 70kg).
- a patient receiving treatment may take a first dose upon waking and then a second dose in the evening (if on a two dose regime) or at 3- or 4-hourly intervals thereafter, and so on.
- the compound may be administered every day (more than once if necessary) after the trigger for die Thl mediated inflammation.
- a slow release device may be used to provide optimal doses of compounds according to the invention to a patient without the need to administer repeated doses.
- the compounds described herein may be used to increase the levels of endogenous production of IL-10 by Th2 cells, dendritic cells and/or
- a pharmaceutical composition comprising a therapeutically effective amount of a compound which is capable of increasing interleukin- 10 (IL-10) production, and a pharmaceutically acceptable vehicle, for use in the treatment of a Thl -mediated disease, wherein the IL-10 is endogenously produced by Th2 cells, dendritic cells and/or macrophages.
- IL-10 interleukin- 10
- the compound is preferably represented by the general formula I.
- the Thl -mediated disease may be an inflammatory disease.
- the composition is preferably an anti-inflammatory pharmaceutical composition.
- a “therapeutically effective amount” of the active compound is any amount which, when administered to a subject, results in increased levels of IL-10, and preferably decreased concentrations of TNF-OC and IL-12, and thereby provides treatment of a Thl -mediated disease.
- the therapeutically effective amount of the active compound used may be between 0.( ⁇ g and 700mg, between 0.7C ⁇ g and 500mg, between lOmg and 450mg, or between 50mg and 150mg.
- a “subject” may be a vertebrate, mammal, or domestic animal, and is preferably a human being.
- medicaments according to the invention may be used to treat any mammal, for example human, livestock, pets, or may be used in other veterinary applications.
- a "pharmaceutically acceptable vehicle” as referred to herein is any combination of known compounds known to those skilled in the art to be useful in formulating pharmaceutical compositions.
- the pharmaceutically acceptable vehicle may be a solid, and the composition may be in the form of a powder or tablet.
- a solid pharmaceutically acceptable vehicle may include one or more substances which may also act as flavouring agents, lubricants, solubilisers, suspending agents, dyes, fillers, glidants, compression aids, inert binders, sweeteners, preservatives, dyes, coatings, or tablet-dis tegrating agents.
- the vehicle may also be an encapsulating material.
- the vehicle is a finely divided solid that is in admixture with the finely divided active agent (i.e. the active compound which increases endogenous IL-10 levels).
- the active agent may be mixed with a vehicle having the necessary compression properties in suitable proportions and compacted in the shape and size desired.
- the powders and tablets preferably contain up to 99% of the active agent.
- Suitable solid vehicles include, for example calcium phosphate, magnesium stearate, talc, sugars, lactose, dextrin, starch, gelatin, cellulose, polyvinylpyrrolidine, low melting waxes and ion exchange resins.
- the pharmaceutical vehicle may be a gel and the composition may be in the form of a cream or the like.
- the pharmaceutical vehicle may be a liquid, and the pharmaceutical composition may be in the form of a solution.
- Liquid vehicles are used in preparing solutions, suspensions, emulsions, syrups, elixirs and pressurized compositions.
- the active compound may be dissolved or suspended in a pharmaceutically acceptable liquid vehicle such as water, an organic solvent, a mixture of both or pharmaceutically acceptable oils or fats.
- the liquid vehicle can contain other suitable pharmaceutical additives such as solubilisers, emulsifiers, buffers, preservatives, sweeteners, flavouring agents, suspending agents, thickening agents, colours, viscosity regulators, stabilizers or osmo-regulators.
- suitable pharmaceutical additives such as solubilisers, emulsifiers, buffers, preservatives, sweeteners, flavouring agents, suspending agents, thickening agents, colours, viscosity regulators, stabilizers or osmo-regulators.
- suitable examples of liquid vehicles for oral and parenteral administration include water (partially containing additives as above, e.g. cellulose derivatives, preferably sodium carboxymethyl cellulose solution), alcohols (including monohydric alcohols and polyhydric alcohols, e.g. glycols) and their derivatives, and oils (e.g. fractionated coconut oil and arachis oil).
- the vehicle can also be an oily ester such as ethyl oleate and isopropyl myristate.
- Sterile liquid vehicles are useful in sterile liquid form compositions for parenteral administration.
- the liquid vehicle for pressurized compositions can be halogenated hydrocarbon or other pharmaceutically acceptable propellant.
- Liquid pharmaceutical compositions which are sterile solutions or suspensions can be utilized by, for example, intramuscular, intrathecal, epidural, intraperitoneal, intravenous and particularly subcutaneous injection.
- the active compound may be prepared as a sterile solid composition that may be dissolved or suspended at the time of administration using sterile water, saline, or other appropriate sterile injectable medium.
- the active compound may be administered orally in the form of a sterile solution or suspension containing other solutes or suspending agents (for example, enough saline or glucose to make the solution isotonic), bile salts, acacia, gelatin, sorbitan monoleate, polysorbate 80 (oleate esters of sorbitol and its anhydrides copolymerized with ethylene oxide) and the like.
- the active compound can also be administered orally either in liquid or solid composition form.
- Compositions suitable for oral administration include solid forms, such as pills, capsules, granules, tablets, and powders, and liquid forms, such as solutions, syrups, elixirs, and suspensions.
- Forms useful for parenteral administration include sterile solutions, emulsions, and suspensions.
- compositions of the invention may be immobilised on or in a support substrate or matrix forming a lipid-rich formulation, which may be used as a delivery device to treat Thl -mediated disorders.
- a drug delivery device comprising:- (i) a pharmaceutical composition comprising a therapeutically effective amount of a compound which is capable of increasing endogenous i terleukin-10 (IL-10) production by Th2 cells, dendritic cells and/or macrophages; and
- the delivery device may be a pessary or a vaginal ring or the like, which may be worn by a subject requiring treatment of a Th -mediated condition.
- the device may be used to treat any disease characterised by a drop in IL-10 concentrations. It is known that the concentration of IL-10 decreases in pregnant women, as a result of foetus tolerance, and this initiates labour during child birth. Thus, the delivery device may be used by pregnant women to prevent or delay premature labour.
- the support matrix may be made of a substrate material which is suitable for supporting the composition therein or thereon.
- the pharmaceutical composition in the device may be the composition of the fourth aspect.
- the composition may be immobilised on the matrix.
- the matrix may comprise any material capable of melting at, or around, body temperature, such that, over time, the matrix dissolves thereby releasing the composition, which is absorbed by the subject.
- the support matrix may a suitable gel or wax.
- suitable gel or wax for example, conventional materials for vaginal administration may be used, such as glycerol, gelatin, glyco-gelatin, macrogols
- Figure 1 shows the chemical structure of one embodiment of a compound represented by formula I, for example a bupropion metabolite, which is denoted herein as BC1053.
- Figure 2 shows the effect of the orally-dosed test compound (BC1053) in vivo on IL-10 levels in mice.
- the compound was administered at 3mg/kg, lOmg/kg and 30mg/kg;
- Figure 3 shows the effect of the compound represented by formula I (BC1053) ex vivo on lipopolysaccharide-induced (LPS) blood cytokine levels in mice blood.
- the compound was administered at lOmg/kg, 30mg/kg and 60mg/kg;
- Figure 4 is a table showing in vivo IL-10 and TNFa concentrations induced by LPS;
- Figure 5 is a table summarising the effect of BC1053 in various disease models, including inter alia the lipopolysaccharide (LPS) model in mouse which is representative of septic shock, dexttan sulphate (DSS) and tti itrobenzene sulfonic acid (TNBS) induced colitis in mice which are representative of inflammatory bowel disease (IBD), and proteolipid protein (PLP) induced experimental autoimmune encephalitis which is representative of multiple sclerosis (MS).
- LPS lipopolysaccharide
- DSS dexttan sulphate
- TNBS tti itrobenzene sulfonic acid
- mice which are representative of inflammatory bowel disease (IBD), and proteolipid protein (PLP) induced experimental autoimmune encephalitis which is representative of multiple sclerosis (MS).
- the table shows the effective doses of the test compound I (e.g. BC1053), and its effect;
- Figure 6 summarises the results of the dextran sulphate (DSS) induced colitis model in mice, which is representative of IBD.
- DSS dextran sulphate
- lOmg/kg and 30mg/kg BC1053 were administered to the DSS-induced mice.
- the corticosteroid dexamethasone was administered at 0.2mg/kg.
- the superior efficacy of BC1053 in a recognised model of IBD is seen compared to the high dose of dexamethasone;
- Figure 7 shows the DSS-induced colitis histology scores.
- the Figure shows 5% DSS only as negative control, 0.2mg/kg dexamethasone as positive control, and lOmg/kg and 30mg/kg of the test compound, BC1053;
- Figure 8 summarises the results of the TNBS-induced colitis model when mice were administered with either 30mg/kg BC1053 or lOmg/kg sulphasalazine (i.e. a sulphonamide antibiotic acting as a positive control).
- the data show the efficacy of administering BC1053 in a recognised model of IBD compared to the high dose of sulphasalazine;
- Figure 9 shows the effect of 30mg/kg BC1053 on TNBS-induced colitis in mice compared to lOmg/kg sulphasalazine, as positive control.
- the mean composite clinical score refers to the mean scores of weight loss, stool consistency and rectal blood;
- FIG. 10 shows additional Thl cytokine (i.e. IL-12) effects of BC1053.
- IL-12 Thl cytokine
- FIG 11 shows additional Thl cytokine (i.e. TNFa) effects of BC1053.
- TNFa Thl cytokine
- Figure 12 shows the effect of BC1053 on proteolipid protein (PLP) induced experimental autoimmune encephalomyelitis (EAE) in SJL mice, which is a representative model of multiple sclerosis (MS).
- PRP proteolipid protein
- EAE experimental autoimmune encephalomyelitis
- the mice were treated with lOmg/kg BC1053, or just the vehicle of 1 % methylcellulose (MC) or were untreated, as controls.
- the graph shows the effects of inducing immuno-tolerance through endogenous IL-10 elevation. Although there was litde effect in the first relapse, the second relapse was prevented in mice treated with BC1053.
- the inventors carried out a range of in vivo and ex vivo experiments in order to determine the effects of various compounds represented by formula I on the endogenous production of the cytokine, IL10.
- the inventors have demonstrated that er thro 2-(l,l- dimemylemyl)amino-l-(3-chiorophenyl)propan-l-ol (denoted herein as BC1053, which is a bupropion metabolite, as shown in Figure 1) surprisingly induces endogenous production of IL-10.
- mice Female BALB/c mice (5 to 7 weeks old) were allowed to acclimatise and were provided with food and water ad libitum. Test compound was dosed orally with either vehicle only (1% carboxymethyl cellulose) or test compound at three doses (3, 10 and 30 mg/kg) in the same vehicle. Half an hour later, each mouse was challenged with a 1 mg/kg (5 ml/kg volume) intraperitoneal injection of lipopolysaccaride (LPS). Two hours after the LPS challenge, terminal blood was taken by cardiac puncture blood and collected in heparinised tubes.
- LPS lipopolysaccaride
- IL-10 concentrations were expressed as pg/ ml.
- mice Female BALB / c mice (5 to 7 weeks old) were allowed to acclimatise and were provided food and water ad libitum. Test compound was dosed orally with either vehicle only (1% carboxymethylcellulose) or test compound at three doses (10, 30 and 60 mg/kg) in the same vehicle. Two and half hours later blood was collected from the treated mice into heparinised tubes and diluted 1 :1 in sterile RPMI. Blood cells were then plated out in triplicate and allowed for 30 minutes. Either LPS (10 g/ml) or phosphate buffered saline were then added and allow to culture for 12 hours after which culture supernatants were collected for IL-10 analysis by Luminex. IL-10 concentrations were then expressed as pg/ml. Dextran sulphate (DSS) induction
- DSS dextran sulphate
- TNBS Tririitrobenzene sulfonic acid
- 5% TNBS in 50% ethanol was given rectally to Balb/ c mice.
- the TNBS initiates colonic inflammation through the disturbance of the mucosal barrier, and thereby results in colonic lesions, diarrhoea, weight loss and rectal bleeding. These symptoms are identical to human colitis, such as Crohn's disease and Ulcerative colitis.
- BC1053 was given orally from day 1 of the TNBS insult, and the mice were monitored.
- PGP Proteolipid protein
- mice (Harlan laboratories, Israel) on day 0, were injected with a single inoculation with freshly prepared proteolipid protein (PLP) solution in an emulsion of complete Freund's adjuvant (CFA), at a ratio of 125 g PLP/ 300 g CFA in 2 X 100 ⁇ subcutaneous injections per mouse.
- PLP proteolipid protein
- CFA complete Freund's adjuvant
- all animals were subjected to supplemental immuno-stimulation with pertussis toxin (PT) (20 ⁇ g/kg ) by intraperitoneal injections on two occasions, once on day 0 of the study and thereafter 48 hours later (day 2).
- PT pertussis toxin
- Plasma B cells can enter mitosis when they encounter an antigen matching their immunoglobulin.
- a mitogen is a chemical substance that triggers signal transduction pathways in which mitogen-activated protein kinase is involved, thereby encouraging a cell to commence cell division, leading to mitosis.
- mitogens can be effectively used to stimulate lymphocytes and therefote assess immune function.
- mitogens can be used to replicate the effects of a Till -mediated disease, such as a viral infection.
- LPS lipopolysaccharide
- BC1053 erythro 2-(l,l- dimethylethyl)amiiio-l-(3-chloropheiiyl)propan-l-ol
- PMBC Peripheral Blood Mononuclear Cells
- Control experiments were conducted in which no LPS was added, such that any effect on the levels of IL10 could be directiy attributed to the presence of the test compound, BC1053.
- FIG. 2 there is shown the effects of different concentrations of BC1053 (3mg/kg, lOmg/kg and 30mg/kg) on the endogenous production levels of IL-10 when measured in vivo.
- concentration of IL-10 increases with increasing concentration of BC1053.
- the fact that the lOmg/kg dosage of BCIO was a little lowet than the 3mg/kg dose may be explained by the effect being maximal at 3 mg/kg, a dose response may well have been defined with lower doses.
- the table shows that BC1053 induces large reduction in TNFa concentrations at all three doses tested (i.e. 3mg/kg, lOmg/kg and 30mg/kg), but that, surprisingly, the concentration of IL-10 significantly increases at all three doses.
- the concentration of IL-10 increases by 44% compared to the control where no BC1053 was added.
- the concentration of IL- 0 increases by 56% at the highest dose tested, i.e. 30mg/kg BC1053.
- Figure 5 is a table showing that various different mouse and rat models can be used to represent human disease conditions.
- septic shock in human can be represented by the lipopolysaccharide (LPS) model in mouse
- rheumatoid arthritis can be represented by the complete Freud's adjuvant induced model in rat
- arthritic swelling can be represented by the carrageenan paw oedema in rat
- IBD inflammatory bowel disease
- DSS dextran sulphate
- TNBS trinitrobenzene sulfonic acid
- MS multiple sclerosis
- PRP proteolipid protein
- FIG. 6 there is shown the data generated from carrying out the DSS-induced colitis model for IBD.
- Two doses of BC1053 (lOmg/kg and 30mg/kg) were administered to the mice, and compared against the control of 0.2mg/kg of the corticosteroid, dexamethasone.
- the inventors were surprised to see that BC 053 was effective at both doses when assessing lesions and diarrhoea.
- diat BO053 has a more complete anti-ulcerative and chsease-modifying effect than a well-known strong corticosteroid (dexamethasone), which has previously been used in the treatment of IBD.
- Figure 7 illustrates the DSS colitis histology scores, and shows that both the lOmg/kg and 30mg/kg doses of BC 1053 were as effective as the positive control, i.e. dexamethasone.
- Figure 8 is a table showing the effects of administering 30mg/kg BC1053 on TNBS- induced mice, as compared to the control of lOmg/kg sulphasalazine (an antibiotic/anti- inflammatory compound) that is commonly used in the treatment of IBD.
- the inventors demonstrated that BC1053 caused an increase in body weight of the treated mice, more effectively than sulphasalazine.
- Lesion score and composite clinical scores for BC1053 were comparable or slighu better than the sulphasalazine.
- the inventors then decided to investigate the effect of BC 1053 on the concentrations of the Thl response cytokines, IL-12 and TNFa, and were annoyed to observe, in an in mm model, that their concentrations dramatically decreased (see Figures 10 and 11). Based on this observation, the inventors hypothesise that BC1053 can be used to effectively increase endogenous levels of IL-10, thereby promoting the switch from a Thl to a Th2 immune response, while simultaneously decreasing the concentration of the Thl cytokines, such as IL-12 and TNFa (and IFNy).
- the inventors have prepared a delivery device made of a support matrix onto which the lipid-rich BC1053 composition is immobilised, and which can be easily used for treating any Thl -mediated disorder.
- the delivery device is formed in the shape of a pessary, with a waxy support matrix.
- Conventional materials for vaginal administration include glycerol/gelatin, gly co-gelatin, macrogols (polyethylene glycols), natural, synthetic or semi-synthetic hard fats, and fractionated palm kernel oil, each having BC1053 immobilised thereon.
- the support matrix melts at body temperature, so that, over time, the composition is released and absorbed by the subject.
- the inventors are aware that premature labour can be caused in pregnant mothers due to a drop in IL-10 concentrations. Therefore, the pessary can be worn by a pregnant woman, such that the BC1053 formulation is released, resulting in an increase in endogenous IL-10 production, thereby preventing premature labour.
- BC1053 shown in Figure 1 not only stimulated production of endogenous IL-10 by Th2 cells, macrophages and dendritic cells, but also acted as an effective Thl cytokine inhibitor (i.e. IL-12 and TNF-oc). They therefore believe that any compound represented by formula (I) may be used as an IL-10 stimulator and as an IL-12 and TNF-oc inhibitor, which can be used in the treatment of any Thl -mediated diseases.
- the results described herein concerning the various established disease models show that BC1053 can be used in the treatment of at least septic shock, rheumatoid arthritis, arthritic swelling, IBD and MS. Indeed, BC1053 has clear effects in the two "difficult" colitis models, and its efficacy is better than dexamethasone, budesonide and sulphasalazine in validated preclinical colitis models.
- BC1053 also has novel and surprising effects in the murine EAE model, a T cell driven model. It was shown to treat relapse (i.e. the antigen drive phase), and so this will find utility across a wide range of Thl driven disease states.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Reproductive Health (AREA)
- Virology (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Gynecology & Obstetrics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Psychiatry (AREA)
- Ophthalmology & Optometry (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
Abstract
The invention relates to the treatment of inflammatory diseases, and especially Th-1 mediated inflammatory diseases. In particular, the invention relates to the treatment of Th- 1 mediated inflammatory diseases using a range of related 1-phenyl-2-amino ethanol, ethanal and ethane derivatives, and to the use of these compounds in methods of treatment.
Description
INFLAMMATORY DISEASE
The present invention relates to the treatment of inflammatory diseases, and especially Th- 1 mediated inflammatory diseases. In particular, the invention relates to the treatment of Th-1 mediated inflammatory diseases using a range of related 1 -phenyl-2-amino ethanol, e hanal and ethane derivatives, and to the use of these compounds in methods of treatment.
The defence against disease is critical for the survival of all animals, and the mechanism employed for this purpose is the animal immune system. The immune system is complex, and involves two main divisions, (i) innate immunity, and (h) adaptive immunity. The innate immune system includes the cells and mechanisms that defend the host from infection by invading organisms, in a non-specific manner. Leukocytes, which are involved with the innate system, include inter alia phagocytic cells, such as macrophages, neutrophils and dendritic cells. The innate system is fully functional before a pathogen enters the host.
In contrast, the adaptive system is only initiated after the pathogen has entered the host, at which point it develops a defence specific to that pathogen. The cells of the adaptive immune system are called lymphocytes, the two main categories of which are B cells and T Cells. B cells are involved in the creation of neutralising antibodies that circulate in blood plasma and lymph and form part of the humoral immune response. T cells play a role in both the humoral immune response and in cell-mediated immunity. There are several subsets of activator or effector T cells, including cytotoxic T cells (CD8+) and "helper" T cells (CD4+), of which there are two main types known as Type 1 helper T cells (Thl) and Type 2 helper T cell (Th2).
Thl cells promote a cell-mediated adaptive immune response, which involves the activation of macrophages and stimulates the release of various cytokines, such as IFNy, TNF- and IL- 2, in response to an antigen. These cytokines influence the function of other cells in the adaptive and innate immune responses, and result in the destruction of micro- organisms. Generally, Thl responses are more effective against intracellular pathogens, such as viruses and bacteria present inside host cells. A Th2 response, however, is characterised by the release of IL-4, which results in the activation of B cells to make neutralising antibodies, which lead the humoral immunity. Th2 responses are more
effective against extracellular pathogens, such as parasites and toxins located outside host cells. Accordingly, the humoral and cell-mediated responses provide quite different mechanisms against an invading pathogen.
Interleukin-10 (IL-10), also known as human cytokine synthesis inhibitory factor (CSIF), is an anti-inflammatory cytokine. It is produced primarily by monocytes and, to a lesser extent, by lymphocytes, and has pleiotropic effects in immunoregulation and inflammation. IL-10 down-regulates the expression of Thl cytokines (such as IFNy, TNF-oc and IL-12), MHC class II antigens, and co-stimulatory molecules on macrophages. It also enhances B cell survival, proliferation, and antibody production. Furthermore, IL-10 can block NF-κΒ activity, and is involved in the regulation of the JAK-STAT signaling pathway. Knockout studies in mice have suggested the function of IL-10 as an essential immunoregulator in the intestinal tract, and patients with Crohn's disease react favorably towards treatment with bacteria producing recombinant IL-10, showing the importance of this cytokine for counteracting excessive immunity in the human body.
IL-10 is a validated target in inflammatory disease, and has been shown to be essential for immunotolerance and the control of Thl immunity (O'Garra et al., 2008, Immunol. Rev., 223:114-31). Systemic adnoinistration of exogenous IL-10 in early clinical trials showed some initial promise in the treatment of various diseases, including rheumatoid arthritis, Crohn's disease, psoriasis and cystic fibrosis. However, problems associated with these early trials were that systemically administered exogenous IL-10 did not dampen exaggerated Thl responses as predicted, possibly because tissue levels of IL-10 were too low (the half-life of IL-10 is short), or because IL-10 was not presented in the correct manner. Hence, concentrations of IFNy, TNF-ot and IL-12 actually increased to deleterious levels. Furthermore, a significant side effect of administering too much exogenous IL-10 is that it actually suppresses the immune system, rather than positively modulating it, and so results in serious immune-related problems.
In view of these problems, there is, therefore, clearly a need in the art for improved medicaments for use in the treatment of Thl -mediated diseases, and especially Thl - mediated inflammatory disorders, which do not suffer the immune-related problems observed in previous IL-10 trials. The inventors have determined that certain related 1-
phenyl-2-amino ethane derivatives have the properties required to be useful in treating such diseases.
Hence, in a first aspect, there is provided a compound which is capable of increasing interleukin-10 (IL-10) production, for use in treating a Thl-mediated disease, wherein the IL-10 is endogenously produced by Th2 cells, dendritic cells and/or macrophages.
In a second aspect of the invention, there is provided a method of preventing, treating and/or ameliorating a Thl-mediated disease, the method comprising administering, to a subject in need of such treatment, a therapeutically effective amount of a compound which is capable of increasing interleukin-10 (IL-10) production, wherein the IL-10 is
endogenously produced by Th2 cells, dendritic cells and/ or macrophages.
In a third aspect, there is provided use of a compound, which is capable of inducing endogenous production of interleukin-10 (IL-10) by Th2 cells, dendritic cells and/or macrophages, for treating a Th-1 mediated disease.
The inventors carried out investigations on a number of different compounds that can induce IL-10 production, as they were aware that IL-10 production is a characteristic that indicates a switch from a Thl to a Th2 response. They have demonstrated that inducing the switch from a Thl to a Th2 response by up-regulating IL-10 production can be used to help treat Thl-mediated hyper-inflammation. Advantageously, by stimulating a Th2 response, by inducing the endogenous release of IL-10, B cells are activated, which produce neutralising antibodies, which lead the humoral immunity. It will be appreciated that Th2 responses are much more effective against extracellular pathogens, such as parasites and toxins located outside host cells, than Thl responses.
By way of example, Thl-mediated hyper-inflammation occurs during viral infections, and so the inventors believe that endogenously producing IL-10 by the Th2 cells upon adrninistration of the compound to the subject could be used to treat a respiratory collapse caused by a viral infection. It is known that some viruses, such as Herpes Simplex Virus (HSV), maintain their presence in the body by stimulating Thl immunity, and that
therefore, triggering a switch to Th2 immunity would help treat herpes infections by allowing the body to attack the virus through natural killer cell immunity.
The inventors are of the view that IL-10 is a paracrine cytokine, and that, therefore, the compound used in the first, second and third aspects of the invention can be effectively used to increase endogenous IL-10 production in a paracrine manner. It will be appreciated that paracrine signalling can be a form of cell signalling in which the target cell is near or local to the signal-releasing cell. Thus, IL-10 can control the immune response at sites of inflammation in tandem with cell-cell interactions.
It is preferred that the compound which is capable of increasing endogenous IL-10 production is recognised by Th2 cells, dendritic cells and/ or macrophages. Thus, Th2 cells, dendritic cells and/or macrophages may phagocytise the compound, react with pathways in each of these cell types, and thereby endogenously produce IL-10. Preferably, therefore, the IL-10 is produced by Th2 cells, dendritic cells and/or macrophages, which are immunocompetent. Advantageously, in contrast to producing IL-10 by non-immune cells, which causes an imbalance in the immune system leading to infections and, in some cases cancer, endogenous production of IL-10 by immuno-competent Th2 cells, dendritic cells and/or macrophages, ensures that the immune system remains balanced, thereby avoiding infection.
Hence, the immune system is capable of regulating itself naturally, thereby reducing the risk of infections and cancer. The levels of IL-10 generated due to the regulator)' process and feedback loops may modulate (e.g. decrease) Thl cytokine concentration, such as IFNy, T F-a and IL-12, but not suppress their production completely. This may be important because these Thl cytokines are needed to protect the body from infection. Thus, by stimulating production of IL-10 endogenously, it is possible to overcome the significant immune-related problems that are observed when the cytokine is added exogenously, resulting in over-production of IFNy, TNF-a and IL-12.
The inventors have determined that certain related 1 -phenyl-2-amino ethane derivatives have the properties required to be useful in treating Thl -mediated diseases. Thus, the
compound, which is capable of increasing endogenous IL-10 production, may comprise a compound of formula I:-
wherein:- X is CO, CHOH or CH2;
R1 is H, or combined with R2;
R2 is H, OH, a halogen, a substituted or unsubstituted amino group, a Cj.5 alkyl or alkoxyl group, optionally substituted with one or more O, OH, amino and/ or optionally C,_3 alkyl substituted phenyl group, or combined with R1;
R3 and R4 are each independendy H, OH, a halogen, a substituted or unsubstituted amino group, or a C,^ alkyl or alkoxyl group, optionally substituted with one or more O, OH, amino and/ or optionally C,.3 alkyl substituted phenyl group;
R5 is H;
R6 is H, a C,_s alkyl group, or combined with R8;
R7 is H, or combined with R8;
R8 is combined with R6 or R7, or is a straight chain, branched or cyclo- C,-C9 alkyl group, optionally including one or more hetero atom in its carbon skeleton and optionally substituted with one or more OH, and/or C5_6 aryl group, optionally substituted with one or more OH or C, 5 alkoxyl or alkyl group;
when combined, R' and R2, together with the associated ring carbon atoms, form an optionally O substituted cycloalkyl, cycloalkenyl, cycloheteroalkyl or cycloheteroalkenyl group of 5 or 6 carbon atoms, or 4 or 5 carbon atoms and a hetero atom;
when combined, R6 and R8, together with the nitrogen atom carrying R8 and the carbon atom carrying R6, form a 5 or 6 membered cycloheteroalkyl group; and,
when combined, R7 and R8, together with the nitrogen atom carrying them, form an optionally benzyl substituted 5 or 6 membered cycloheteroalkyl group;
or a pharmaceutically acceptable salt or solvate thereof.
R2 can be a hydroxyalkyl group, or include a carbonyloxy group and is, preferably, H, OH, HOCH2-, 0=CHNH-, CH3PhCOO-, NH2COO-, or a halogen, preferably chlorine. R2 is more preferably H, OH or CI. R3 is preferably H, NH2, OH or CH3PhCOO-. R3 is more preferably H, NH, or OH. R4 is preferably H, OH, NH2COO-, or a halogen, preferably, chlorine. R4 is more preferably H or CI. R6 is preferably methyl, ethyl, or H, more preferably, methyl or ethyl and most preferably methyl. R7 is preferably H. R8 is preferably straight chain or branched C2-C6 alkyl group, optionally substituted with OH, phenyl, PhOH or PhOCH3. R8 is more preferably tert. butyl, isopropyl, -C(CH3)2OH, - CH2PhOCH3,-(CH2)2PhOH, -CH(CH3)CH2CH2Ph, or -CH(CH3)CH2CH2PhOH and, most preferably, tert. butyl, -C(CH3)2OH, -(CH,)2PhOH, -CH(CH3)CH2CH2Ph, or - CH(CH3)CH2CH2PhOH. R8 can also be:-
When combined, R1 and R2 preferably form the group:-
When R6 and R8 are combined it is preferred that, together with the nitrogen atom carrying R8 and the carbon atom carrying R6, they form a cycloheteroalkyl group of 5 carbon atoms and 1 nitrogen atom. When R' and R8 are combined it is preferred that they form the group:-
In the foregoing, Ph means phenyl and it is preferred that, when bi-substituted, any such phenyl group is 1, 4-substituted.
In preferred embodiments, the present invention involves a compound of formula I wherein:- X is CO, CHOH or CH2;
R' is H;
R2 is H, OH, or a halogen;
R3 is H, OH or NH2;
R4 is H, or a halogen;
R5 is H;
R> is H, methyl or ethyl, or combined with R8;
R7 is H, or combined with R8;
R8 is combined with R6 or R7, or is tert. butyl, -C(CH3)2OH, -(CH^PhOH, - CH(CH3)CH2CH2Ph, or -CH(CH3)CH2CH2PhOH;
when combined, R6 and R8, together with the nitrogen atom carrying R8 and the carbon atom carrying R6, form a cycloheteroalkyl group of 5 carbon atoms and 1 nitrogen atom; and,
when R7 and R8 are
or a pharmaceutically acceptable salt or solvate thereof.
In all embodiments of the invention where Rs is not combined with R8, it is preferred for Rs to be a methyl or an ethyl gtoup, preferably a methyl group. In such preferred embodiments, it is also preferred that R1, R4, R5 and R7 are H, R2 is H or OH, and R3 is OH. In such preferred embodiments R8 can be -(CH^PhOH or - CH(CH3)CH2CH2PhOH.
As described in the Examples, the inventors studied the effects of erytbro 2-(l,l- dimethylemyl)aniino-l-(3-chlorophenyr)propan-l-ol (denoted herein as BC1053, shown in Figure 1) and demonstrated in in vim and ex vivo models that (i) this compound surprisingly induces endogenous production of IL-10 by Th2 cells, dendritic cells and/or macrophages and (ii) the concentrations of the Thl cytokines, TNF-CC and IL- 2, were potently inhibited. Thus, the invention is based on the induction of Th2 immune cells to trigger the switch from a Thl to a Th2 immune response, and to thereby treat Thl -mediated hyper- inflammation, which is driven by these Thl cytokines.
The inventors therefore believe that they are the first to demonstrate that, in addition to sharing other properties, the defined 1 -phenyl-2-amino ethanol, ethanal and ethane derivatives represented by Formula I can be used to stimulate endogenous production of IL-10, and reduce Thl cytokine production, and to thereby induce the switch from a Thl to a Th2 response, in such a way so as to be useful in the treatment of Thl -mediated inflammatory disease. In particular, these compounds may be used to combat respiratory disorders that are caused by acute viral infections, and which, in some cases (e.g. influenza infections), can cause death. Various metabolites of compound (I) (i.e. any compound of formula (I)) may also be used for stimulating endogenous production of IL-10 from Th2 cells, dendritic cells and/or macrophages. Compound (I), for use, in the invention, may be chiral. Hence, the compound (I) may include any diastereomer and enantiomer of the formula represented by (I). Diastereomers or enantiomers of (I) are believed to display potent cytokine modulatory activity, and such activities may be determined by use of appropriate in vitro and in vivo assays, which will be known to the skilled technician. It will also be appreciated that compounds for use in the invention may also include pharmaceutically active salts, e.g. the hydrochloride. In another embodiment, the compound represented by formula (I) may be the drug that is known and available under the trade name, bupropion. Bupropion is known to be metabolised in vivo into a number of different metabolites also of formula (I), an embodiment of which is shown in Figure 1. Therefore, buproprion or any of these metabolites may also be used for treating acute viral infections in accordance with the invention. Bupropion is metabolised non-stereoselectively to a number of enantiomers, but these compounds represent a relatively small proportion of the total metabolism of the parent drug. Compounds defined by formula (I) can therefore include these metabolites as racemates or as pairs of diastereoisomers or individual enantiomers, including the tbreo- and erytbrv-pah of diastereoisomers and the individual tbreo and erythro enantiomers. It is preferred that the compound defined by formula (I) includes the erythro enantiomer or enantiomers.
- Si -
Exemplary bupropion metabolites include 2-(l,l-dime ylemyl)amino-l-(3- chlorophenyl)propan-l -ol, 2-(l ,1 -dimemyl-2-hydroxyethyl)amino-l -(3- chlorophenyl)propan-l -one, (1 S,2R)-erythto-2-(l ,1 -dimemylemyl)amino~l-(3- chlorophenyl)propan-l -ol, (1 R,2S)-erythro-2-(l ,1 -d½iethylemyl)arnino-l -(3- chlorophenyl)propan-l-ol, (lS,2S)-tJiieo-2-(l,l-dimemylemyl)arnino-l-(3- chlorophenyl)propan-l -ol and (1 R,2R)-threo-2-(l,l -dimemylemyl)amino-l -(3- chlorophenyl)propan- 1 -ol.
In anodier embodiment, compound (I) may be hydrobupropion (i.e. 2-(l,l- dimemylemyl)amino-l-(3-chlorophenyl)propan-l-ol). One isomer of hydrobupropion may be (+)-^reo-hydrobupropion, i.e. (R, R-hydrobupropion), and another isomer may be
It is preferred that the bupropion metabolite employed in any aspect of the invention is an R enantiomer, either at the first and/or second position.
Numerous disease conditions are believed to be associated with low levels of IL-10 (i.e. hypo-IL-10 disorders), or in situations where an increase in IL-10 concentration is either too slow or insufficient, and any of these condition may be treated in accordance with the invention. Preferably, the Thl -mediated disease, which may be treated, may be a Thl- mediated inflammatory disease, preferably systemic inflammatory disease. As described in the examples, the inventors have conducted several experiments in mice models which are known to be representative of human disease, for example septic shock, rheumatoid arthritis (RA), arthritic swelling, inflammatory bowel disease (IBD) and multiple sclerosis (MS).
Hence, the disease to be treated may be selected from a group of Thl -mediated diseases consisting of rheumatoid arthritis (RA); psoriatic arthritis; psoriasis; inflammatory bowel syndrome (IBD); Crohn's disease; ulcerative colitis; multiple sclerosis (MS); flu, including pandemic flu; respiratory disorders, for example those caused by viruses, such as respirator}' syncytial virus (RSV); cystic fibrosis; herpes, including genital herpes; asthma and allergies; sepsis and septic shock; bacterial pneumonia; bacterial meningitis; dengue
hemorrhagic fever; diabetes Type I; endometriosis; prostatitis; uveitis; uterine ripening; and age-related macular degeneration.
The Thl -mediated disease may be virally, bacterially or chemically (e.g. environmentally) induced. For example, a virus causing the Thl -mediated disease may cause a chronic or acute infection, which may cause a respiratory disorder. Suitably, the virus causing the Thl- mediated disease may be Influenza.
Preferably, the Thl -mediated disease, which may be treated, is systemic inflammatory disease, for example flarnmatory bowel syndrome (IBD) or rheumatoid arthritis ( A).
It will be appreciated that the active compound may be used to treat a Thl -mediated disease in a monotherapy (i.e. use of the compound capable of stimulating endogenous IL- 10 production alone). Alternatively, the compound may be used as an adjunct to, or in combination with, known therapies used in treating Thl-mediated diseases.
The active compound may be combined in compositions having a number of different forms depending, in particular, on the manner in which the composition is to be used. Thus, for example, the composition may be in the form of a powder, tablet, capsule, liquid, ointment, cream, gel, hydrogel, aerosol, spray, micellar solution, transdermal patch, liposome suspension or any other suitable form that may be administered to a person or animal in need of treatment. It will be appreciated that the vehicle for medicaments according to the invention should be one which is well-tolerated by the subject to whom it is given, and preferably enables delivery of the agents across the blood-brain barrier, or the lungs.
Compositions comprising the active compound may be used in a number of ways. For instance, oral adrninistration may be required in which case the compound may be contained within a composition that may, for example, be ingested orally in the form of a tablet, capsule or liquid. Alternatively, the composition may be administered by injection into the blood stream. Injections may be intravenous (bolus or infusion) or subcutaneous (bolus or infusion). Alternatively, the composition comprising the active compound may be administered by inhalation (e.g. intranasally, or by mouth).
Compositions may also be formulated for topical use. For instance, ointments may be applied to the skin. Topical application to the skin is particularly useful for treating infections of the skin or as a means of transdermal delivery to other tissues.
It will be appreciated that the amount of the active compound that is required is determined by its biological activity and bioavailability, which in turn depends on the mode of administration, the physicochemical properties of the compound and whether the compound is being used as a monotherapy, or in a combined therapy. The frequency of administration will also be influenced by the above-mentioned factors and particularly the half-life of the active compound within the subject being treated.
Optimal dosages to be administered may be determined by those skilled in the art, and will vary with the particular active compound in use, the strength of the preparation, the mode of administration, and the advancement of the disease condition. Additional factors depending on the particular subject being treated will result in a need to adjust dosages, including subject age, weight, gender, diet, and time of adrninistration.
It will be appreciated that a skilled person will be able to calculate required doses, and optimal concentrations of the active compound at a target tissue, based upon the pharmacokinetics of the active. Known procedures, such as those conventionally employed by the pharmaceutical industry (eg in vivo experimentation, clinical trials, etc.), may be used to establish specific formulations of the active compound and precise therapeutic regimes (such as daily doses of the compounds and the frequency of administtation).
Generally, a daily dose of between 0.00^g/kg of body weight and 60mg/kg of body weight of the active compound may be used for the prevention and/or treatment of a Thl- mediated disease depending upon which compound is used. Suitably, the daily dose is between 0.01|Ig/kg of body weight and 30mg/kg of body weight, more suitably between 0.01(Ig/kg of body weight and lOmg/kg of body weight or between 0.1(Xg/kg and 5mg/kg body weight, and most suitably between approximately O.lJIg/kg and 3mg/kg body weight.
Daily doses of the active compound may be given as a single administration (e.g. a single daily injection or a single inhalation). A suitable daily dose may be between 0.07μg and 700mg (i.e. assuming a body weight of 70kg), or between 0.7C^g and 500mg, or between lOmg nd 450mg.
It is envisaged that medicaments comprising the active compound may be administered more than once to the subject in need of treatment. The compound may require administration twice or more times during a day. As an example, the active compound may be administered as two (or more depending upon the severity of the viral infection being treated) daily doses of between 0.(^g and 700mg (i.e. assuming a body weight of 70kg). A patient receiving treatment may take a first dose upon waking and then a second dose in the evening (if on a two dose regime) or at 3- or 4-hourly intervals thereafter, and so on. It is envisaged that the compound may be administered every day (more than once if necessary) after the trigger for die Thl mediated inflammation.
Alternatively, a slow release device may be used to provide optimal doses of compounds according to the invention to a patient without the need to administer repeated doses.
Based on their findings that the compounds described herein may be used to increase the levels of endogenous production of IL-10 by Th2 cells, dendritic cells and/or
macrophages, and thereby reduce the levels of Thl cytokines, such as T F-OC and IL-12, to trigger the Thl to Th2 switch, the inventors believe that these effects of the compounds may be harnessed and used in the manufacture of clinically useful compositions. Hence, in a fourth aspect, there is provided a pharmaceutical composition comprising a therapeutically effective amount of a compound which is capable of increasing interleukin- 10 (IL-10) production, and a pharmaceutically acceptable vehicle, for use in the treatment of a Thl -mediated disease, wherein the IL-10 is endogenously produced by Th2 cells, dendritic cells and/or macrophages.
The compound is preferably represented by the general formula I.
The Thl -mediated disease may be an inflammatory disease. Thus, the composition is preferably an anti-inflammatory pharmaceutical composition.
A "therapeutically effective amount" of the active compound is any amount which, when administered to a subject, results in increased levels of IL-10, and preferably decreased concentrations of TNF-OC and IL-12, and thereby provides treatment of a Thl -mediated disease.
For example, the therapeutically effective amount of the active compound used may be between 0.(^g and 700mg, between 0.7C^g and 500mg, between lOmg and 450mg, or between 50mg and 150mg.
A "subject" may be a vertebrate, mammal, or domestic animal, and is preferably a human being. Hence, medicaments according to the invention may be used to treat any mammal, for example human, livestock, pets, or may be used in other veterinary applications.
A "pharmaceutically acceptable vehicle" as referred to herein is any combination of known compounds known to those skilled in the art to be useful in formulating pharmaceutical compositions.
In one embodiment, the pharmaceutically acceptable vehicle may be a solid, and the composition may be in the form of a powder or tablet. A solid pharmaceutically acceptable vehicle may include one or more substances which may also act as flavouring agents, lubricants, solubilisers, suspending agents, dyes, fillers, glidants, compression aids, inert binders, sweeteners, preservatives, dyes, coatings, or tablet-dis tegrating agents. The vehicle may also be an encapsulating material. In powders, the vehicle is a finely divided solid that is in admixture with the finely divided active agent (i.e. the active compound which increases endogenous IL-10 levels). In tablets, the active agent may be mixed with a vehicle having the necessary compression properties in suitable proportions and compacted in the shape and size desired. The powders and tablets preferably contain up to 99% of the active agent. Suitable solid vehicles include, for example calcium phosphate, magnesium stearate, talc, sugars, lactose, dextrin, starch, gelatin, cellulose, polyvinylpyrrolidine, low melting waxes and ion exchange resins.
SUBSTITUTE SHEET (RULE 26
In another embodiment, the pharmaceutical vehicle may be a gel and the composition may be in the form of a cream or the like. In yet another embodiment, the pharmaceutical vehicle may be a liquid, and the pharmaceutical composition may be in the form of a solution. Liquid vehicles are used in preparing solutions, suspensions, emulsions, syrups, elixirs and pressurized compositions. The active compound may be dissolved or suspended in a pharmaceutically acceptable liquid vehicle such as water, an organic solvent, a mixture of both or pharmaceutically acceptable oils or fats. The liquid vehicle can contain other suitable pharmaceutical additives such as solubilisers, emulsifiers, buffers, preservatives, sweeteners, flavouring agents, suspending agents, thickening agents, colours, viscosity regulators, stabilizers or osmo-regulators. Suitable examples of liquid vehicles for oral and parenteral administration include water (partially containing additives as above, e.g. cellulose derivatives, preferably sodium carboxymethyl cellulose solution), alcohols (including monohydric alcohols and polyhydric alcohols, e.g. glycols) and their derivatives, and oils (e.g. fractionated coconut oil and arachis oil). For parenteral administration, the vehicle can also be an oily ester such as ethyl oleate and isopropyl myristate. Sterile liquid vehicles are useful in sterile liquid form compositions for parenteral administration. The liquid vehicle for pressurized compositions can be halogenated hydrocarbon or other pharmaceutically acceptable propellant.
Liquid pharmaceutical compositions which are sterile solutions or suspensions can be utilized by, for example, intramuscular, intrathecal, epidural, intraperitoneal, intravenous and particularly subcutaneous injection. The active compound may be prepared as a sterile solid composition that may be dissolved or suspended at the time of administration using sterile water, saline, or other appropriate sterile injectable medium.
The active compound may be administered orally in the form of a sterile solution or suspension containing other solutes or suspending agents (for example, enough saline or glucose to make the solution isotonic), bile salts, acacia, gelatin, sorbitan monoleate, polysorbate 80 (oleate esters of sorbitol and its anhydrides copolymerized with ethylene oxide) and the like. The active compound can also be administered orally either in liquid or solid composition form. Compositions suitable for oral administration include solid forms, such as pills, capsules, granules, tablets, and powders, and liquid forms, such as solutions,
syrups, elixirs, and suspensions. Forms useful for parenteral administration include sterile solutions, emulsions, and suspensions.
The inventors also beKeve that compositions of the invention may be immobilised on or in a support substrate or matrix forming a lipid-rich formulation, which may be used as a delivery device to treat Thl -mediated disorders.
Hence, in a fifth aspect of the invention, there is provided a drug delivery device comprising:- (i) a pharmaceutical composition comprising a therapeutically effective amount of a compound which is capable of increasing endogenous i terleukin-10 (IL-10) production by Th2 cells, dendritic cells and/or macrophages; and
(ii) a support matrix. The delivery device may be a pessary or a vaginal ring or the like, which may be worn by a subject requiring treatment of a Th -mediated condition. For example, the device may be used to treat any disease characterised by a drop in IL-10 concentrations. It is known that the concentration of IL-10 decreases in pregnant women, as a result of foetus tolerance, and this initiates labour during child birth. Thus, the delivery device may be used by pregnant women to prevent or delay premature labour.
The support matrix may be made of a substrate material which is suitable for supporting the composition therein or thereon. The pharmaceutical composition in the device may be the composition of the fourth aspect. The composition may be immobilised on the matrix. In one embodiment, the matrix may comprise any material capable of melting at, or around, body temperature, such that, over time, the matrix dissolves thereby releasing the composition, which is absorbed by the subject.
The support matrix may a suitable gel or wax. For example, conventional materials for vaginal administration may be used, such as glycerol, gelatin, glyco-gelatin, macrogols
(polyethylene glycols), natural, synthetic or semi-synthetic hard fats, and fractionated palm kernel oil.
All of the features described herein (including any accompanying claims, abstract and drawings), and/ or all of the steps of any method or process so disclosed, may be combined with any of the above aspects in any combination, except combinations where at least some of such features and/or steps are mutually exclusive.
Embodiments of the invention will now be further described, by way of example only, with reference to the following Examples, and to the accompanying diagrammatic drawings, in which: -
Figure 1 shows the chemical structure of one embodiment of a compound represented by formula I, for example a bupropion metabolite, which is denoted herein as BC1053.
References to the compound BC1053 herein refer to the compound shown in Figure 1;
Figure 2 shows the effect of the orally-dosed test compound (BC1053) in vivo on IL-10 levels in mice. The compound was administered at 3mg/kg, lOmg/kg and 30mg/kg;
Figure 3 shows the effect of the compound represented by formula I (BC1053) ex vivo on lipopolysaccharide-induced (LPS) blood cytokine levels in mice blood. The compound was administered at lOmg/kg, 30mg/kg and 60mg/kg;
Figure 4 is a table showing in vivo IL-10 and TNFa concentrations induced by LPS;
Figure 5 is a table summarising the effect of BC1053 in various disease models, including inter alia the lipopolysaccharide (LPS) model in mouse which is representative of septic shock, dexttan sulphate (DSS) and tti itrobenzene sulfonic acid (TNBS) induced colitis in mice which are representative of inflammatory bowel disease (IBD), and proteolipid protein (PLP) induced experimental autoimmune encephalitis which is representative of multiple sclerosis (MS). The table shows the effective doses of the test compound I (e.g. BC1053), and its effect;
Figure 6 summarises the results of the dextran sulphate (DSS) induced colitis model in mice, which is representative of IBD. lOmg/kg and 30mg/kg BC1053 were administered to the DSS-induced mice. As a control, the corticosteroid dexamethasone was administered at 0.2mg/kg. The superior efficacy of BC1053 in a recognised model of IBD is seen compared to the high dose of dexamethasone;
Figure 7 shows the DSS-induced colitis histology scores. The Figure shows 5% DSS only as negative control, 0.2mg/kg dexamethasone as positive control, and lOmg/kg and 30mg/kg of the test compound, BC1053;
Figure 8 summarises the results of the TNBS-induced colitis model when mice were administered with either 30mg/kg BC1053 or lOmg/kg sulphasalazine (i.e. a sulphonamide antibiotic acting as a positive control). The data show the efficacy of administering BC1053 in a recognised model of IBD compared to the high dose of sulphasalazine;
Figure 9 shows the effect of 30mg/kg BC1053 on TNBS-induced colitis in mice compared to lOmg/kg sulphasalazine, as positive control. The mean composite clinical score refers to the mean scores of weight loss, stool consistency and rectal blood;
Figure 10 shows additional Thl cytokine (i.e. IL-12) effects of BC1053. μΜ and 10 μΜ BC1053 was administered to IL-12 explants. As can be seen, there is a clear reduction in IL-12 in the explant administered with 10 μΜ BC1053;
Figure 11 shows additional Thl cytokine (i.e. TNFa) effects of BC1053. Ι Μ and 10 μΜ BC1053 was administered to TNFa explants. As can be seen there is a clear reduction in IL-12 in the explant administered with 10 μΜ BC1053; and
Figure 12 shows the effect of BC1053 on proteolipid protein (PLP) induced experimental autoimmune encephalomyelitis (EAE) in SJL mice, which is a representative model of multiple sclerosis (MS). The mice were treated with lOmg/kg BC1053, or just the vehicle of 1 % methylcellulose (MC) or were untreated, as controls. The graph shows the effects of inducing immuno-tolerance through endogenous IL-10 elevation. Although there was litde effect in the first relapse, the second relapse was prevented in mice treated with BC1053.
Examples
The inventors carried out a range of in vivo and ex vivo experiments in order to determine the effects of various compounds represented by formula I on the endogenous production of the cytokine, IL10. The inventors have demonstrated that er thro 2-(l,l- dimemylemyl)amino-l-(3-chiorophenyl)propan-l-ol (denoted herein as BC1053, which is a bupropion metabolite, as shown in Figure 1) surprisingly induces endogenous production of IL-10.
Furthermore, they have demonstrated in various well-known and established mouse models that increasing endogenous production of IL-10 can be used to treat various human diseases, including septic shock, inflammatory bowel disease (IBD) and multiple sclerosis (MS). They have also shown that compounds of Formula I are able to reduce, in an in vivo model, the concentrations of both IL-12 and TNFa, which are Thl response cytokines (as
is IFNy). Therefore, it is clear from the data described below that compounds, which are capable of increasing endogenous IL-10 production by immuno-competent Th2 cells, macrophages and dendritic cells can be effectively used for treating Thl -mediated diseases. Materials and Methods
In vivo lipopolysaccharide (LPS) induction
Female BALB/c mice (5 to 7 weeks old) were allowed to acclimatise and were provided with food and water ad libitum. Test compound was dosed orally with either vehicle only (1% carboxymethyl cellulose) or test compound at three doses (3, 10 and 30 mg/kg) in the same vehicle. Half an hour later, each mouse was challenged with a 1 mg/kg (5 ml/kg volume) intraperitoneal injection of lipopolysaccaride (LPS). Two hours after the LPS challenge, terminal blood was taken by cardiac puncture blood and collected in heparinised tubes. Samples were put on ice until they were centrifuged (6000xg for 5 minutes at 4°C), and the supernatant plasma was aliquoted, snap frozen in liquid nitrogen and then stored at -20°C. Plasma was analysed by ELISA technique for IL-10 levels. IL-10 concentrations were expressed as pg/ ml.
Ex vivo LPS induction
Female BALB / c mice (5 to 7 weeks old) were allowed to acclimatise and were provided food and water ad libitum. Test compound was dosed orally with either vehicle only (1% carboxymethylcellulose) or test compound at three doses (10, 30 and 60 mg/kg) in the same vehicle. Two and half hours later blood was collected from the treated mice into heparinised tubes and diluted 1 :1 in sterile RPMI. Blood cells were then plated out in triplicate and allowed for 30 minutes. Either LPS (10 g/ml) or phosphate buffered saline were then added and allow to culture for 12 hours after which culture supernatants were collected for IL-10 analysis by Luminex. IL-10 concentrations were then expressed as pg/ml. Dextran sulphate (DSS) induction
5% dextran sulphate (DSS) was given to the drinking water of BDF1 mice. The DSS initiates colonic inflammation through the disturbance of the mucosal barrier, and thereby results in colonic lesions, diarrhoea, weight loss and rectal bleeding. These symptoms are
identical to human colitis, such as Crohn's disease and Ulcerative colitis. BC1053 was given orally from day 1 of the DSS insult, and the mice were monitored.
Tririitrobenzene sulfonic acid (TNBS) induction
5% TNBS in 50% ethanol was given rectally to Balb/ c mice. The TNBS initiates colonic inflammation through the disturbance of the mucosal barrier, and thereby results in colonic lesions, diarrhoea, weight loss and rectal bleeding. These symptoms are identical to human colitis, such as Crohn's disease and Ulcerative colitis. BC1053 was given orally from day 1 of the TNBS insult, and the mice were monitored.
TNBS cytokine explant experiments
1 cm piece of distal colon was removed, from animals in the TNBS experiments, faeces were removed and the piece was placed in 2-3 ml of Roswell Park Memorial Institute (RPMI) medium. Colons were washed 3 times using supplemented RPMI by vigorous shaking. The explants was placed in 1 ml of fresh sterile supplemented RPMI and cultured overnight, with and without 1 and ΙΟμΜ of BC1053.
Proteolipid protein (PLP) induced experimental autoimmune encephalomyelitis (EAE) in SJL mice
SJL mice (Harlan laboratories, Israel) on day 0, were injected with a single inoculation with freshly prepared proteolipid protein (PLP) solution in an emulsion of complete Freund's adjuvant (CFA), at a ratio of 125 g PLP/ 300 g CFA in 2 X 100 μΐ subcutaneous injections per mouse. In order to increase the blood brain barrier penetration all animals were subjected to supplemental immuno-stimulation with pertussis toxin (PT) (20 μg/kg ) by intraperitoneal injections on two occasions, once on day 0 of the study and thereafter 48 hours later (day 2). The same animals were also treated with either oral gavage of vehicle (water) or 10 mg/kg of BC1053, once a day, throughout the course of the experiment. Through the entire experiment (42 days), animals were checked daily for clinical signs (general observations of the health of the animal), body weights and EAE clinical scores (0 to 5 scale: 0 being no signs of neurological signs, 1 being distal tail limp and droop, 2 being hind leg weakness and paresis, wobbily walk and/or hind legs unsteady, 3 being hind leg paralysis, when moving animal dragging its hind legs, 4 being quadriplegia, full paralysis, animal unable to move, thin and emaciated and 5 being moribund or dead.
Example 1— Stimulation Experiments using the mitogen. LPS
Plasma B cells can enter mitosis when they encounter an antigen matching their immunoglobulin. A mitogen is a chemical substance that triggers signal transduction pathways in which mitogen-activated protein kinase is involved, thereby encouraging a cell to commence cell division, leading to mitosis. Thus, mitogens can be effectively used to stimulate lymphocytes and therefote assess immune function. By stimulating lymphocytes, mitogens can be used to replicate the effects of a Till -mediated disease, such as a viral infection.
The mitogen that the inventors used to stimulate lymphocytes, and therefore assess immune function, was lipopolysaccharide (LPS), which acts on B cells but not T cells. The effects of embodiments of die compound represented by formula I, i.e. erythro 2-(l,l- dimethylethyl)amiiio-l-(3-chloropheiiyl)propan-l-ol (BC1053), on the levels of IL-10 were investigated in LPS stimulated assays. Peripheral Blood Mononuclear Cells (PMBC) were independently administered with LPS, and then treated with BC1053. Control experiments were conducted in which no LPS was added, such that any effect on the levels of IL10 could be directiy attributed to the presence of the test compound, BC1053. (a) Effect of BC1053 on LPS-induced blood IL-10 levels in mice
Referring to Figure 2, there is shown the effects of different concentrations of BC1053 (3mg/kg, lOmg/kg and 30mg/kg) on the endogenous production levels of IL-10 when measured in vivo. In general, the concentration of IL-10 increases with increasing concentration of BC1053. The fact that the lOmg/kg dosage of BCIO was a little lowet than the 3mg/kg dose may be explained by the effect being maximal at 3 mg/kg, a dose response may well have been defined with lower doses.
(b) Effect of orally dosed BC1053 on ex vivo stimulated IL-10 in murine blood
Referring to Figure 3, there is shown the effects of different concentrations of BC1053 (lOmg/kg, 30mg/kg and 60mg/kg) on the production levels of IL-10 after extracted blood is stimulated with LPS (ex vivo). The concentration of ex vivo stimulated IL-10 increases with increasing concentration of BC1053.
(c) In vivo cytokine experiments using LPS induction
Referring to Figure 4, the table shows that BC1053 induces large reduction in TNFa concentrations at all three doses tested (i.e. 3mg/kg, lOmg/kg and 30mg/kg), but that, surprisingly, the concentration of IL-10 significantly increases at all three doses. As can be seen, at the lowest dose of only 3mg/kg BC1053, the concentration of IL-10 increases by 44% compared to the control where no BC1053 was added. The concentration of IL- 0 increases by 56% at the highest dose tested, i.e. 30mg/kg BC1053.
Example 2 - Effect of BC1053 on Dextran sulphate DSS)-induced colitis mice
Figure 5 is a table showing that various different mouse and rat models can be used to represent human disease conditions. For example, (i) septic shock in human can be represented by the lipopolysaccharide (LPS) model in mouse, (ii) rheumatoid arthritis can be represented by the complete Freud's adjuvant induced model in rat, (iii) arthritic swelling can be represented by the carrageenan paw oedema in rat, (iv) inflammatory bowel disease (IBD) can be represented by the dextran sulphate (DSS) and trinitrobenzene sulfonic acid (TNBS) induced colitis model in mice, and multiple sclerosis (MS) can be represented by the proteolipid protein (PLP) induced experimental autoimmune encephalitis model in SJL mice. Referring to Figure 6, there is shown the data generated from carrying out the DSS-induced colitis model for IBD. Two doses of BC1053 (lOmg/kg and 30mg/kg) were administered to the mice, and compared against the control of 0.2mg/kg of the corticosteroid, dexamethasone. The inventors were surprised to see that BC 053 was effective at both doses when assessing lesions and diarrhoea. Overall, these data suggest diat BO053 has a more complete anti-ulcerative and chsease-modifying effect than a well-known strong corticosteroid (dexamethasone), which has previously been used in the treatment of IBD.
Figure 7 illustrates the DSS colitis histology scores, and shows that both the lOmg/kg and 30mg/kg doses of BC 1053 were as effective as the positive control, i.e. dexamethasone.
Example 3 - Effect of BC 1053 on TNBS-induced colitis mice
Figure 8 is a table showing the effects of administering 30mg/kg BC1053 on TNBS- induced mice, as compared to the control of lOmg/kg sulphasalazine (an antibiotic/anti-
inflammatory compound) that is commonly used in the treatment of IBD. The inventors demonstrated that BC1053 caused an increase in body weight of the treated mice, more effectively than sulphasalazine. Lesion score and composite clinical scores for BC1053 were comparable or slighu better than the sulphasalazine.
Referring to Figure 9, there is shown the effect of BC1053 on the mean composite clinical score over 8 days compared to sulphasalazine. The inventors were surprised to observe that BC1053 successfully reduced the score over the time period tested. These data demonstrate that BC1053, through the raising of IL-10, has the ability to improve modelled IBD.
Example 4 - Effect of BC1053 on T BS cytokine explants
The inventors then decided to investigate the effect of BC 1053 on the concentrations of the Thl response cytokines, IL-12 and TNFa, and were surprised to observe, in an in mm model, that their concentrations dramatically decreased (see Figures 10 and 11). Based on this observation, the inventors hypothesise that BC1053 can be used to effectively increase endogenous levels of IL-10, thereby promoting the switch from a Thl to a Th2 immune response, while simultaneously decreasing the concentration of the Thl cytokines, such as IL-12 and TNFa (and IFNy).
Example 5 - Effect of BC 1053 on PLP-induced EAE in SJL mice
As shown in Figure 12, the inventors used an established model which is representative of multiple sclerosis. They demonstrated that BC1053 effectively prevents a second relapse, whereas the two controls (untreated mice and mice treated with only the vehicle) did not.
Example 6 - Pessary
The inventors have prepared a delivery device made of a support matrix onto which the lipid-rich BC1053 composition is immobilised, and which can be easily used for treating any Thl -mediated disorder. The delivery device is formed in the shape of a pessary, with a waxy support matrix. Conventional materials for vaginal administration that have been used include glycerol/gelatin, gly co-gelatin, macrogols (polyethylene glycols), natural, synthetic or semi-synthetic hard fats, and fractionated palm kernel oil, each having BC1053
immobilised thereon. The support matrix melts at body temperature, so that, over time, the composition is released and absorbed by the subject.
The inventors are aware that premature labour can be caused in pregnant mothers due to a drop in IL-10 concentrations. Therefore, the pessary can be worn by a pregnant woman, such that the BC1053 formulation is released, resulting in an increase in endogenous IL-10 production, thereby preventing premature labour.
Summary
In summary, the inventors were surprised to observe that compound, BC1053 shown in Figure 1, not only stimulated production of endogenous IL-10 by Th2 cells, macrophages and dendritic cells, but also acted as an effective Thl cytokine inhibitor (i.e. IL-12 and TNF-oc). They therefore believe that any compound represented by formula (I) may be used as an IL-10 stimulator and as an IL-12 and TNF-oc inhibitor, which can be used in the treatment of any Thl -mediated diseases. For example, the results described herein concerning the various established disease models show that BC1053 can be used in the treatment of at least septic shock, rheumatoid arthritis, arthritic swelling, IBD and MS. Indeed, BC1053 has clear effects in the two "difficult" colitis models, and its efficacy is better than dexamethasone, budesonide and sulphasalazine in validated preclinical colitis models.
BC1053 also has novel and surprising effects in the murine EAE model, a T cell driven model. It was shown to treat relapse (i.e. the antigen drive phase), and so this will find utility across a wide range of Thl driven disease states.
Claims
1. A compound which is capable of increasing i terleukin-10 (IL-10) production, for use in treating a Thl -mediated disease, wherein the IL-10 is endogenously produced by Th2 cells, dendritic cells and/ or macrophages.
2. A compound according to claim 1, wherein the compound is used to increase endogenous IL-10 production in a paracrine manner.
3. A compound according to any preceding claim, wherein the compound modulates Thl cytokine concentration, such as IFNy, TNF-a and IL-12.
4. A compound according to any preceding claim, wherein the compound has formula I:-
wherein: -
X is CO, CHOH or CH2;
R1 is H, or combined with R2;
R2 is H, OH, a halogen, a substituted or unsubstituted amino group, a C s alkyl or alkoxyl group, optionally substituted with one or more O, OH, amino and/or optionally C1.3 alkyl substituted phenyl group, or combined with R1;
R3 and R4 are each independently H, OH, a halogen, a substituted or unsubstituted amino group, or a Q.5 alkyl or alkoxyl group, optionally substituted with one or more O, OH, amino and/or optionally C1 3 alkyl substituted phenyl group;
R5 is H;
R6 is H, a C s alkyl group, or combined with R8;
R7 is H, or combined with R8;
R8 is combined with Re or R7, or is a straight chain, branched or cyclo- CrC9 alkyl group, optionally including one or more heteto atom in its carbon skeleton and optionally substituted with one or more OH, and/or C5 6 aryl group, optionally substituted with one or more OH or C,_s alkoxyl or alkyl group;
when combined, R1 and R2, together with the associated ring carbon atoms, form an optionally O substituted cycloalkyl, cycloalkenyl, cycloheteroalkyl or cycloheteroalkenyl group of 5 or 6 carbon atoms, or 4 or 5 carbon atoms and a hetero atom;
when combined, R6 and R8, together widi the nitrogen atom carrying R8 and the carbon atom carrying Rr', form a 5 or 6 membered cycloheteroalkyl group; and,
when combined, R7 and R8, togedier with the nitrogen atom carrying them, form an optionally benzyl substituted 5 or 6 membered cycloheteroalkyl group;
or a pharmaceutically acceptable salt or solvate thereof.
5. A compound according to claim 4, wherein R2 is a hydroxyalkyl group, or a carbonyloxy group and is, preferably, H, OH, HOCH2-, 0=CHNH-, CH3PhCOO-,
NH2COO-, or a halogen, optionally wherein R2 is H, OH or CI.
6. A compound according to either claim 4 or 5, wherein R3 is H, NH2, OH or CH3PhCOO-
7. A compound according to any one of claims 4-6, wherein R3 is H, NH2 or OH.
8. A compound according to any one of claims 4-7, wherein R4 is H, OH, NH2COO-, or a halogen, optionally wherein R4 is H or CI.
9. A compound according to any one of claims 4-8, wherein R6 is methyl, ethyl, or H.
10. A compound according to any one of claims 4-9, wherein R7 is H. 11. A compound according to any one of claims 4-10, wherein R8 is a straight chain or branched C2-C5 alkyl group, optionally substituted with OH, phenyl, PhOH or PhOCH3, optionally wherein R8 is tert. butyl, isopropyl, -C(CH3)2OH, -CH2PhOCH3,-(CH2)2PhOH, - CH(C¾)CH,CH2Ph, or -CH(CH3)CH2CH2PhOH.
compound according to any one of claims 4-10, wherein R1
13. A compound according to any one of claims 4-12, wherein when combined, R1 and 2 form the group:-
14. A compound according to any one of claims 4- 3, wherein when R6 and R8 are combined, together with the nitrogen atom carrying R8 and the carbon atom carrying R6, they form a cycloheteroalkyl group of 5 carbon atoms and 1 nitrogen atom.
15. A compound according to any one of claims 4-14, wherein when R7 and R8 are combined they form the group:-
16. A compound according to any one of claims 4-15, wherein the compound (I) includes any diastereomer and enantiomer of the formula represented by (1). 17. A compound according to any preceding claim, wherein the compound is bupropion or a metabolite thereof.
18. A compound according to claim 17, wherein the bupropion metabolite dimemylemyi) amino- l-(3-chlorophenyI)propan- 1 -ol, 2 (1,1 -dimethyl-2- hydroxye Ayl)amino-l -(3-chlorophenyl)propan-l -one, (1 S,2R)-erythro-2-(l ,1 -
dimemylemyl)amino- 1 -(3-chlorophenyl)propan- 1 -ol, (lR,2S)-erythro-2-(i , 1 - dimethylemyl)amino-l -(3-chloiophenyl)ptopan-l -ol, 1 S,2S)-threo-2-(l ,1- dimethylethyl) amino- 1 - (3 -chlorophenyl)propan- -ol, or (1 R,2 ) -threo-2- (1 , 1 - dimethylemyl)amino-l-(3-chlorophenyl)propan-l-ol.
19. A compound according to any one of claims 4-18, wherein the compound defined by formula (I) includes the erythro enantiomer or enantiomers.
20. A compound according to any preceding claim, wherein the Thl -mediated disease, which may be treated, is a Thl -mediated inflammatory disease, preferably systemic inflammatory disease.
21. A compound according to claim 20, wherein compound is used to stimulate endogenous production of IL-10, and reduce Thl cytokine production, and to thereby induce the switch from a Thl to a Th2 response, in such a way so as to be useful in the treatment of Th -mediated inflammatory disease.
22. A compound according to any preceding claim, wherein the Thl -mediated disease to be treated is selected from a group of Thl -mediated diseases consisting of rheumatoid arthritis (RA); psoriatic arthritis; psoriasis; inflammatory bowel syndrome (IBD); Crohn's disease; ulcerative colitis; multiple sclerosis (MS); flu, including pandemic flu; respiratory disorders, for example those caused by viruses, such as respiratory syncytial virus (RSV); cystic fibrosis; herpes, including genital herpes; asthma and allergies; sepsis and septic shock; bacterial pneumonia; bacterial meningitis; dengue hemorrhagic fever; diabetes Type I; endometriosis; prostatitis; uveitis; uterine ripening; age-related macular degeneration; and virally, bacterially or chemically induced Thl -mediated diseases.
23. A compound according to claim 22, wherein the Thl -mediated disease to be treated is inflammatory bowel syndrome (IBD) or rheumatoid arthritis (RA).
24. A pharmaceutical composition comprising a therapeutically effective amount of a compound as defined in any one of claims 1-23, and a pharmaceutically acceptable vehicle, for use in the treatment of a Thl -mediated disease, wherein the IL-10 is endogenously produced by Th2 cells, dendritic cells and/ or macrophages.
25. A drug delivery device comprising: -
(i) a pharmaceutical composition comprising a therapeutically effective amount of a compound which is capable of increasing endogenous interleukin-10 (IL-10) production by Th2 cells, dendritic cells and/or macrophages; and (ii) a support matrix.
26. A drug delivery device according to claim 25, wherein the device comprises the pharmaceutical composition defined in claim 24. 27. A drug delivery device according to either claim 25 or claim 26, wherein the device is a pessary or a vaginal ring, or the like.
28. A drug delivery device according to any one of claims 25 to 27, wherein the device is worn by a subject requiring treatment of a Thl -mediated condition.
29. A drug delivery device according to any one of claims 25 to 28, wherein the delivery device is used by pregnant women to prevent or delay premature labour.
30. A drug delivery device according to any one of claims 25 to 29, wherein the support matrix comprises a material capable of melting at, or around, body temperature, such that, over time, the matrix dissolves thereby releasing the composition, which is absorbed by the subject.
31. A drug delivery device according to any one of claims 25 to 30, wherein the support matrix is a gel or wax, for example glycerol/gelatin, glyco-gelatin, macrogol (e.g.
polyethylene glycol), natural, synthetic or semi-synthetic hard fat, or fractionated palm kernel oil.
32. A method of preventing, treating and / or ameliorating a Th -mediated disease, the method comprising administering, to a subject in need of such treatment, a therapeutically effective amount of a compound as defined in any one claims 1-23.
33. Use of a compound as defined in any one of claims 1 -23, for inducing endogenous production of interkukin-10 (IL-10) by Th2 cells, dendritic cells and/or macrophages, for treating a Th-1 mediated disease.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB1018302.8 | 2010-10-29 | ||
GB1018302.8A GB2484977A (en) | 2010-10-29 | 2010-10-29 | Treatment of a Th-1 mediated disease |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2012056229A1 true WO2012056229A1 (en) | 2012-05-03 |
Family
ID=43401517
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB2011/052073 WO2012056229A1 (en) | 2010-10-29 | 2011-10-25 | Inflammatory disease |
Country Status (2)
Country | Link |
---|---|
GB (1) | GB2484977A (en) |
WO (1) | WO2012056229A1 (en) |
Citations (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0147719A2 (en) * | 1983-12-24 | 1985-07-10 | Tanabe Seiyaku Co., Ltd. | Novel carbostyril derivative and process for preparing same |
WO1999013862A2 (en) * | 1997-09-12 | 1999-03-25 | Columbia Laboratories (Bermuda) Limited | A pharmaceutical composition for treating dysmenorrhea and premature labor |
EP1051971A1 (en) * | 1999-05-10 | 2000-11-15 | Pierce Management, L.L.P. | Patch and method for transdermal delivery of bupropion base |
US20050085551A1 (en) * | 1999-12-07 | 2005-04-21 | Reindler Christopher W. | Bupropion to treat viral diseases |
WO2005089741A2 (en) * | 2004-03-17 | 2005-09-29 | Sosei R&D Ltd. | The treatment of inflammatory disorders and pain using beta-aminoalcohols |
US20060173080A1 (en) * | 2002-09-14 | 2006-08-03 | The Regents Of The University Of California | Methods of modulating TNF using bupropion |
WO2007034200A1 (en) * | 2005-09-21 | 2007-03-29 | Sosei R & D Ltd. | 2-aminoalcohols for the treatment of neurodegenerative diseases |
WO2007060458A2 (en) * | 2005-11-24 | 2007-05-31 | Sosei R & D Ltd. | Treatment of ophthalmic diseases with beta-amino alcohols |
WO2007096782A2 (en) * | 2006-02-22 | 2007-08-30 | Valorisation Recherche Hscm, Limited Partnership | Compositions for disorders associated wtth metachromatic cell activation |
WO2007102019A1 (en) * | 2006-03-09 | 2007-09-13 | Sosei R & D Ltd. | The use of bupropion metabolites for the treatment of inflammatory disorders |
US20080138397A1 (en) * | 2006-10-24 | 2008-06-12 | Aradigm Corporation | Processes for taste-masking of inhaled formulations |
WO2008087418A2 (en) * | 2007-01-17 | 2008-07-24 | Philip Braithwaite | Device |
WO2010034779A2 (en) * | 2008-09-24 | 2010-04-01 | The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin | Composition and method for treatment of preterm labor |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050234024A1 (en) * | 2004-04-14 | 2005-10-20 | Clarke David E | Materials and methods for the treatment of ulcerative colitis |
-
2010
- 2010-10-29 GB GB1018302.8A patent/GB2484977A/en not_active Withdrawn
-
2011
- 2011-10-25 WO PCT/GB2011/052073 patent/WO2012056229A1/en active Application Filing
Patent Citations (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0147719A2 (en) * | 1983-12-24 | 1985-07-10 | Tanabe Seiyaku Co., Ltd. | Novel carbostyril derivative and process for preparing same |
WO1999013862A2 (en) * | 1997-09-12 | 1999-03-25 | Columbia Laboratories (Bermuda) Limited | A pharmaceutical composition for treating dysmenorrhea and premature labor |
EP1051971A1 (en) * | 1999-05-10 | 2000-11-15 | Pierce Management, L.L.P. | Patch and method for transdermal delivery of bupropion base |
US20050085551A1 (en) * | 1999-12-07 | 2005-04-21 | Reindler Christopher W. | Bupropion to treat viral diseases |
US20060173080A1 (en) * | 2002-09-14 | 2006-08-03 | The Regents Of The University Of California | Methods of modulating TNF using bupropion |
WO2005089741A2 (en) * | 2004-03-17 | 2005-09-29 | Sosei R&D Ltd. | The treatment of inflammatory disorders and pain using beta-aminoalcohols |
WO2007034200A1 (en) * | 2005-09-21 | 2007-03-29 | Sosei R & D Ltd. | 2-aminoalcohols for the treatment of neurodegenerative diseases |
WO2007060458A2 (en) * | 2005-11-24 | 2007-05-31 | Sosei R & D Ltd. | Treatment of ophthalmic diseases with beta-amino alcohols |
WO2007096782A2 (en) * | 2006-02-22 | 2007-08-30 | Valorisation Recherche Hscm, Limited Partnership | Compositions for disorders associated wtth metachromatic cell activation |
WO2007102019A1 (en) * | 2006-03-09 | 2007-09-13 | Sosei R & D Ltd. | The use of bupropion metabolites for the treatment of inflammatory disorders |
US20080138397A1 (en) * | 2006-10-24 | 2008-06-12 | Aradigm Corporation | Processes for taste-masking of inhaled formulations |
WO2008087418A2 (en) * | 2007-01-17 | 2008-07-24 | Philip Braithwaite | Device |
WO2010034779A2 (en) * | 2008-09-24 | 2010-04-01 | The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin | Composition and method for treatment of preterm labor |
Non-Patent Citations (1)
Title |
---|
O'GARRA ET AL., IMMUNOL. REV., vol. 223, 2008, pages 114 - 31 |
Also Published As
Publication number | Publication date |
---|---|
GB201018302D0 (en) | 2010-12-15 |
GB2484977A (en) | 2012-05-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2702109C1 (en) | Combined therapy for treating hepatitis b infections | |
GB2487808A (en) | Oral adjuvant or formulation comprising a lipid and an alcohol | |
JPH09509136A (en) | Pharmaceutical composition for immunopotentiating treatment | |
US12005049B2 (en) | Methods of preventing cancer metastasis | |
US20170029391A1 (en) | Cyclohexenyl compounds, compositions comprising them and methods | |
CN111346081B (en) | New use of pharmaceutical composition comprising n-pentanoic acid, indolpropanic acid and sodium n-butyrate | |
KR20080017296A (en) | Compounds having immunomodulator activity | |
ES2959799T3 (en) | Methods to suppress suppressor cells of myeloid origin in patients | |
CN111202737B (en) | Application of tripterine amide derivative in preparation of medicine for treating autoimmune diseases | |
US20050261246A1 (en) | Methods for treating inflammatory and autoimmune diseases | |
CN116589606B (en) | Butyrylated yeast glucan as well as preparation method and application thereof | |
US12042485B2 (en) | Methods of minimizing cancer metastasis | |
CN109475549B (en) | Pharmaceutical composition and use thereof for treating autoimmune diseases | |
WO2012056229A1 (en) | Inflammatory disease | |
CN104000822A (en) | Compound cold medicinal composition containing bilastine | |
RU2721282C2 (en) | Method for treating multiple sclerosis (versions) | |
CN111803487B (en) | Application of ginkgolide in preparation of medicine for preventing and/or treating Guillain-Barre syndrome | |
CN107617101B (en) | Zoledronic acid-containing and interleukin-containing medium pharmaceutical combination of element 2 and application thereof | |
JP2005518438A (en) | Use of biosynthetic estriol diester prodrugs to treat autoimmune diseases | |
CA3101041A1 (en) | Structurally modified fatty acids for improving glycemic control and treating inflammatory bowel disease | |
CN115645385B (en) | Application of licochalcone B in preparation of medicines for treating and/or preventing type I interferon diseases | |
EP3621628A1 (en) | Method for treating multiple sclerosis using arsenic trioxide | |
CN113855670B (en) | Application of A205804 in preparation of medicines for treating sepsis | |
US9192602B2 (en) | Indication of anthra[2,1,c][1,2,5]thiadiazole-6,11-dione compound in alleviating pain | |
CN117137897B (en) | Application of sofalcone in preparation of medicine for preventing/treating psoriasis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11778940 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 11778940 Country of ref document: EP Kind code of ref document: A1 |